https://trial.medpath.com/news/single-injection-of-zilebesiran-reduces-blood-pressure-by-up-to-12-mmhg-in-phase-2-trial 2024-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/single-injection-of-zilebesiran-reduces-blood-pressure-by-up-to-12-mmhg-in-phase-2-trial 2024-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/axsome-therapeutics-announces-successful-completion-of-phase-3-clinical-trial-for-alzheimers-disease-agitation 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/axsome-therapeutics-announces-successful-completion-of-phase-3-clinical-trial-for-alzheimers-disease-agitation 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/microbot-medical-secures-key-patent-for-modular-robotic-system-expanding-market-potential-to-6-million-procedures 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/microbot-medical-secures-key-patent-for-modular-robotic-system-expanding-market-potential-to-6-million-procedures 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clene-advances-cnm-au8-toward-potential-als-approval-with-fda-meetings-and-biomarker-analysis 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clene-advances-cnm-au8-toward-potential-als-approval-with-fda-meetings-and-biomarker-analysis 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-expanded-use-of-trikafta-for-cystic-fibrosis-treatment 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-expanded-use-of-trikafta-for-cystic-fibrosis-treatment 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-for-verastem-oncology-s-new-drug-application-for-recurrent-kras-mutant-lgsoc-treatment 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-for-verastem-oncology-s-new-drug-application-for-recurrent-kras-mutant-lgsoc-treatment 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/igc-pharma-expands-calma-phase-2-trial-for-alzheimer-s-agitation-treatment-with-new-oklahoma-site 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/igc-pharma-expands-calma-phase-2-trial-for-alzheimer-s-agitation-treatment-with-new-oklahoma-site 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/signatera-mrd-test-shows-exceptional-survival-outcomes-in-muscle-invasive-bladder-cancer-surveillance 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/signatera-mrd-test-shows-exceptional-survival-outcomes-in-muscle-invasive-bladder-cancer-surveillance 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aspire-biopharma-s-sublingual-aspirin-shows-twice-faster-action-in-heart-attack-treatment-trial 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aspire-biopharma-s-sublingual-aspirin-shows-twice-faster-action-in-heart-attack-treatment-trial 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/carvykti-r-is-the-first-and-only-bcma-targeted 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carvykti-r-is-the-first-and-only-bcma-targeted 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/odronextamab-demonstrates-high-efficacy-in-lymphoma-treatments-at-ash-meeting 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/odronextamab-demonstrates-high-efficacy-in-lymphoma-treatments-at-ash-meeting 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-and-biogen-initiate-phase-3-emperor-trial-for-zorevunersen-in-dravet-syndrome 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stoke-therapeutics-and-biogen-initiate-phase-3-emperor-trial-for-zorevunersen-in-dravet-syndrome 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-ptc-therapeutics-nda-for-sepiapterin-to-treat-pku 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-ptc-therapeutics-nda-for-sepiapterin-to-treat-pku 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-aficamten-shows-superior-cardiac-benefits-over-standard-treatment-in-hypertrophic-cardiomyopathy 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-aficamten-shows-superior-cardiac-benefits-over-standard-treatment-in-hypertrophic-cardiomyopathy 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-announces-alignment-with-global-regulatory-agencies 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stoke-therapeutics-announces-alignment-with-global-regulatory-agencies 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-confirms-superior-efficacy-of-perioperative-immunotherapy-plus-chemotherapy-in-resectable-nsclc 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-confirms-superior-efficacy-of-perioperative-immunotherapy-plus-chemotherapy-in-resectable-nsclc 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-launches-phase-3-trial-of-mk-1084-plus-pembrolizumab-for-kras-g12c-mutated-nsclc 2024-04-04T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-launches-phase-3-trial-of-mk-1084-plus-pembrolizumab-for-kras-g12c-mutated-nsclc 2024-04-04T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-driven-real-world-evidence-revolution-new-paradigm-for-biotech-companies 2024-04-04T06:44:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-driven-real-world-evidence-revolution-new-paradigm-for-biotech-companies 2024-04-04T06:44:19+00:00 weekly 0.7 https://trial.medpath.com/news/india-launches-world-s-most-affordable-car-t-cell-therapy-at-one-tenth-international-cost 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-launches-world-s-most-affordable-car-t-cell-therapy-at-one-tenth-international-cost 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/caribou-biosciences-expands-clinical-development-of-cb-010-with-fda-clearance-of-ind-in-lupus 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caribou-biosciences-expands-clinical-development-of-cb-010-with-fda-clearance-of-ind-in-lupus 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tpvr-with-self-expanding-harmony-valve-associated-with 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tpvr-with-self-expanding-harmony-valve-associated-with 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-requires-fast-track-designation-for-subcutaneous-formulation-of-leqembi-for-alzheimer-s-disease 2024-04-03T21:04:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-requires-fast-track-designation-for-subcutaneous-formulation-of-leqembi-for-alzheimer-s-disease 2024-04-03T21:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/court-rules-in-favor-of-arbutus-in-patent-dispute-over-moderna-s-covid-19-vaccine-delivery-technology 2024-04-03T19:06:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/court-rules-in-favor-of-arbutus-in-patent-dispute-over-moderna-s-covid-19-vaccine-delivery-technology 2024-04-03T19:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/ind-application-submitted-to-fda-for-synkir-310-trial-in-relapsed-refractory-b-nhl 2024-04-03T16:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ind-application-submitted-to-fda-for-synkir-310-trial-in-relapsed-refractory-b-nhl 2024-04-03T16:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-strategic-decisions-shaping-the-future-of-cell-and-gene-therapy-development 2024-04-03T04:20:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-strategic-decisions-shaping-the-future-of-cell-and-gene-therapy-development 2024-04-03T04:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/behavioral-science-emerges-as-key-strategy-for-driving-adoption-of-novel-therapies-in-biopharma 2024-04-03T01:32:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/behavioral-science-emerges-as-key-strategy-for-driving-adoption-of-novel-therapies-in-biopharma 2024-04-03T01:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-receives-fda-approval-for-first-denosumab-biosimilars-in-us-and-canada 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sandoz-receives-fda-approval-for-first-denosumab-biosimilars-in-us-and-canada 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-of-adjuvant-cemiplimab-versus-placebo-after-surgery-for-high-risk-cutaneous-squamous-cell-carcinoma 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-of-adjuvant-cemiplimab-versus-placebo-after-surgery-for-high-risk-cutaneous-squamous-cell-carcinoma 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-hits-reset-on-drug-from-2-5b-deal-after-lower-than-projected-efficacy-in-trials 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-hits-reset-on-drug-from-2-5b-deal-after-lower-than-projected-efficacy-in-trials 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-completes-zanidatamab-biologics-license-application-for-previously-treated-her2-positive-metastatic-biliary-tract-cancer 2024-04-02T18:04:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-completes-zanidatamab-biologics-license-application-for-previously-treated-her2-positive-metastatic-biliary-tract-cancer 2024-04-02T18:04:38+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-preference-for-bladder-sparing-treatments-in-high-risk-nmibc-patients 2024-04-02T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-highlights-preference-for-bladder-sparing-treatments-in-high-risk-nmibc-patients 2024-04-02T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer 2024-04-02T01:04:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer 2024-04-02T01:04:35+00:00 weekly 0.7 https://trial.medpath.com/news/direct-and-selective-pharmacological-disruption-of-the-yap 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/direct-and-selective-pharmacological-disruption-of-the-yap 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eflornithine-for-neuroblastoma-ema-approval-timelines-and-how-to-avoid 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eflornithine-for-neuroblastoma-ema-approval-timelines-and-how-to-avoid 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/agios-strategy-shift-pays-off-with-fda-approval-of-first-drug-for-rare 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-strategy-shift-pays-off-with-fda-approval-of-first-drug-for-rare 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pharmaessentia-interferon-drug-for-a-rare-type-of-blood 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pharmaessentia-interferon-drug-for-a-rare-type-of-blood 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cretostimogene-monotherapy-demonstrated-75-2-complete-response-rate-in 2024-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cretostimogene-monotherapy-demonstrated-75-2-complete-response-rate-in 2024-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-denali-neuro-drug-fails-mid-stage-trial-in-als-ms-study-is 2024-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-denali-neuro-drug-fails-mid-stage-trial-in-als-ms-study-is 2024-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-mfars-in-pediatric-friedreich-s-ataxia-insights-from-the-fachild-study 2024-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-mfars-in-pediatric-friedreich-s-ataxia-insights-from-the-fachild-study 2024-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-sequel-s-twiist-aid-system-first-insulin-pump-to-directly-measure-every-micro-dose 2024-03-30T19:00:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-sequel-s-twiist-aid-system-first-insulin-pump-to-directly-measure-every-micro-dose 2024-03-30T19:00:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-flexes-its-new-accelerated-approval-authorities-hoping-to 2024-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-flexes-its-new-accelerated-approval-authorities-hoping-to 2024-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/milestone-pharmaceuticals-announces-resubmission-of-new-drug-application-for-etripamil-for-treatment-in-paroxysmal-supraventricular-tachycardia 2024-03-28T19:03:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/milestone-pharmaceuticals-announces-resubmission-of-new-drug-application-for-etripamil-for-treatment-in-paroxysmal-supraventricular-tachycardia 2024-03-28T19:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-announces-clinical-development-plan-for-resubmission-of-new-drug-application-for-reproxalap-in-dry-eye-disease 2024-03-28T19:03:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-therapeutics-announces-clinical-development-plan-for-resubmission-of-new-drug-application-for-reproxalap-in-dry-eye-disease 2024-03-28T19:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-national-medical-products-administration-accepts 2024-03-28T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-s-national-medical-products-administration-accepts 2024-03-28T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-shows-consistent-benefit-in-resectable-nsclc-regardless-of-neoadjuvant-treatment-duration 2024-03-28T14:05:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-shows-consistent-benefit-in-resectable-nsclc-regardless-of-neoadjuvant-treatment-duration 2024-03-28T14:05:51+00:00 weekly 0.7 https://trial.medpath.com/news/vicore-s-buloxibutid-shows-promising-lung-function-improvement-in-phase-2a-ipf-trial 2024-03-28T10:08:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vicore-s-buloxibutid-shows-promising-lung-function-improvement-in-phase-2a-ipf-trial 2024-03-28T10:08:25+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-provides-fda-update-on-pdufa-target-action-date-for-govorestat-for-the-treatment-of-classic-galactosemia 2024-03-28T00:03:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/applied-therapeutics-provides-fda-update-on-pdufa-target-action-date-for-govorestat-for-the-treatment-of-classic-galactosemia 2024-03-28T00:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/u-k-becomes-the-first-country-to-release-detailed-data-on-sponsors-that-fail-to-register-clinical-trials 2024-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-k-becomes-the-first-country-to-release-detailed-data-on-sponsors-that-fail-to-register-clinical-trials 2024-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-2023-full-year-results-and-2024-outlook 2024-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-announces-2023-full-year-results-and-2024-outlook 2024-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-joint-ventures-from-2016-2024 2024-03-27T20:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-joint-ventures-from-2016-2024 2024-03-27T20:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-s-obesity-drug-shows-promising-results-in-reducing-fat-with-minimal-muscle-loss 2024-03-27T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/altimmune-s-obesity-drug-shows-promising-results-in-reducing-fat-with-minimal-muscle-loss 2024-03-27T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-warns-against-high-concentration-lidocaine-products-in-cosmetic-procedures 2024-03-27T10:58:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-warns-against-high-concentration-lidocaine-products-in-cosmetic-procedures 2024-03-27T10:58:50+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-stok-up-on-upbeat-dravet-syndrome-study-data 2024-03-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stoke-therapeutics-stok-up-on-upbeat-dravet-syndrome-study-data 2024-03-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-priority-review-of-nda-for-revumenib-for-the-treatment-of-relapsed-refractory-kmt2ar-acute-leukemia 2024-03-26T02:03:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-announces-fda-priority-review-of-nda-for-revumenib-for-the-treatment-of-relapsed-refractory-kmt2ar-acute-leukemia 2024-03-26T02:03:21+00:00 weekly 0.7 https://trial.medpath.com/news/intrabio-announces-u-s-fda-accepts-new-drug-application-for-ib1001-for-the-treatment-of-niemann-pick-disease-type-c 2024-03-26T02:03:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intrabio-announces-u-s-fda-accepts-new-drug-application-for-ib1001-for-the-treatment-of-niemann-pick-disease-type-c 2024-03-26T02:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/avecho-launches-largest-phase-iii-trial-of-cbd-for-insomnia-in-australia 2024-03-26T00:57:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avecho-launches-largest-phase-iii-trial-of-cbd-for-insomnia-in-australia 2024-03-26T00:57:22+00:00 weekly 0.7 https://trial.medpath.com/news/chugai-s-vabysmo-receives-japanese-approval-for-retinal-vein-occlusion-treatment 2024-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chugai-s-vabysmo-receives-japanese-approval-for-retinal-vein-occlusion-treatment 2024-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-shows-belumosudil-s-efficacy-in-treating-chronic-graft-versus-host-disease 2024-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-study-shows-belumosudil-s-efficacy-in-treating-chronic-graft-versus-host-disease 2024-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pancreatic-cancer-survivor-funds-clinical-trial-to-aid-future-patients 2024-03-25T17:48:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pancreatic-cancer-survivor-funds-clinical-trial-to-aid-future-patients 2024-03-25T17:48:32+00:00 weekly 0.7 https://trial.medpath.com/news/lipocine-completes-dosing-in-pivotal-study-for-oral-postpartum-depression-treatment-lpcn-1154 2024-03-25T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipocine-completes-dosing-in-pivotal-study-for-oral-postpartum-depression-treatment-lpcn-1154 2024-03-25T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-complete-response-letters-for-regeneron-s-odronextamab-in-non-hodgkin-lymphoma 2024-03-25T07:54:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-complete-response-letters-for-regeneron-s-odronextamab-in-non-hodgkin-lymphoma 2024-03-25T07:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/chemomab-secures-global-patent-protection-for-cm-101-antibody-targeting-primary-sclerosing-cholangitis 2024-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemomab-secures-global-patent-protection-for-cm-101-antibody-targeting-primary-sclerosing-cholangitis 2024-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaceutical-industry-leadership-shuffle-major-executive-appointments-signal-strategic-shifts-across-biotech-and-pharma 2024-03-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmaceutical-industry-leadership-shuffle-major-executive-appointments-signal-strategic-shifts-across-biotech-and-pharma 2024-03-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-review-of-the-clinical-efficacy-of-fda-approved-antibody 2024-03-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-review-of-the-clinical-efficacy-of-fda-approved-antibody 2024-03-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pan-foundation-study-reveals-c-grade-for-u-s-healthcare-access-highlighting-systemic-disparities 2024-03-22T09:13:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pan-foundation-study-reveals-c-grade-for-u-s-healthcare-access-highlighting-systemic-disparities 2024-03-22T09:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/biophytis-advances-ruvembri-to-phase-3-trial-for-sarcopenia-treatment-following-promising-phase-2-results 2024-03-22T07:01:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biophytis-advances-ruvembri-to-phase-3-trial-for-sarcopenia-treatment-following-promising-phase-2-results 2024-03-22T07:01:04+00:00 weekly 0.7 https://trial.medpath.com/news/dermata-therapeutics-advances-phase-3-trial-for-novel-once-weekly-acne-treatment-dmt310 2024-03-21T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dermata-therapeutics-advances-phase-3-trial-for-novel-once-weekly-acne-treatment-dmt310 2024-03-21T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-patent-office-upholds-umeclidinium-vilanterol-combination-patent-despite-opposition-challenges 2024-03-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-patent-office-upholds-umeclidinium-vilanterol-combination-patent-despite-opposition-challenges 2024-03-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-revolutionizes-drug-discovery-industry-leaders-share-latest-advances-at-london-conference 2024-03-21T07:01:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-revolutionizes-drug-discovery-industry-leaders-share-latest-advances-at-london-conference 2024-03-21T07:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-support-services-market-set-to-reach-47-1-billion-by-2032-amid-growing-outsourcing-trend 2024-03-21T05:53:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-support-services-market-set-to-reach-47-1-billion-by-2032-amid-growing-outsourcing-trend 2024-03-21T05:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/elixir-medical-receives-fda-breakthrough-device-designation-for-the-dynamx-btk-system-for-use-in-the-treatment-of-chronic-limb-threatening-ischemia-resulting-from-below-the-knee-arterial-disease 2024-03-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elixir-medical-receives-fda-breakthrough-device-designation-for-the-dynamx-btk-system-for-use-in-the-treatment-of-chronic-limb-threatening-ischemia-resulting-from-below-the-knee-arterial-disease 2024-03-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/scandion-oncology-reports-promising-updated-phase-ii-corist-data 2024-03-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scandion-oncology-reports-promising-updated-phase-ii-corist-data 2024-03-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-updates-on-clinical-trials-and-financials-for-2023 2024-03-20T12:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-updates-on-clinical-trials-and-financials-for-2023 2024-03-20T12:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-pembrolizumab-combo-misses-survival-endpoints-in-endometrial-cancer-trial 2024-03-20T11:54:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenvatinib-pembrolizumab-combo-misses-survival-endpoints-in-endometrial-cancer-trial 2024-03-20T11:54:57+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-reports-promising-early-stage-data-for-thyroid-eye-disease-treatment 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-reports-promising-early-stage-data-for-thyroid-eye-disease-treatment 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-for-dfd-29-for-rosacea-treatment 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-new-drug-application-for-dfd-29-for-rosacea-treatment 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stat-readout-orchard-acelyrin-novo-astrazeneca 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stat-readout-orchard-acelyrin-novo-astrazeneca 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-announces-positive-phase-1-2-poc-data-for-first-subcutaneous-anti-igf-1r-to-demonstrate-clinical-responses-in-thyroid-eye-disease 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-announces-positive-phase-1-2-poc-data-for-first-subcutaneous-anti-igf-1r-to-demonstrate-clinical-responses-in-thyroid-eye-disease 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-study-on-friedreich-s-ataxia-aims-to-enhance-understanding-and-treatment 2024-03-19T19:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-study-on-friedreich-s-ataxia-aims-to-enhance-understanding-and-treatment 2024-03-19T19:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-s-amycretin-pill-shows-promising-13-weight-loss-in-early-trial 2024-03-19T15:32:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-s-amycretin-pill-shows-promising-13-weight-loss-in-early-trial 2024-03-19T15:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-plans-to-resubmit 2024-03-19T14:27:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-announces-plans-to-resubmit 2024-03-19T14:27:37+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-prepares-to-seek-approval-for-menopause-drug-elinzanetant-following-positive-phase-3-trial-results 2024-03-19T11:58:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-prepares-to-seek-approval-for-menopause-drug-elinzanetant-following-positive-phase-3-trial-results 2024-03-19T11:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/nvidia-expands-ai-healthcare-footprint-with-major-drug-discovery-partnerships 2024-03-19T07:01:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nvidia-expands-ai-healthcare-footprint-with-major-drug-discovery-partnerships 2024-03-19T07:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/petros-pharmaceuticals-successfully-launches-ai-tool-in 2024-03-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/petros-pharmaceuticals-successfully-launches-ai-tool-in 2024-03-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-non-opioid-pain-medications-hold-promise-but-face-challenges 2024-03-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-non-opioid-pain-medications-hold-promise-but-face-challenges 2024-03-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ocuterra-s-phase-ii-diabetic-retinopathy-trial-fails-to-meet-endpoints 2024-03-15T09:57:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocuterra-s-phase-ii-diabetic-retinopathy-trial-fails-to-meet-endpoints 2024-03-15T09:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-early-referral-system-to-expand-car-t-cell-access-in-large-b-cell-lymphoma 2024-03-15T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-call-for-early-referral-system-to-expand-car-t-cell-access-in-large-b-cell-lymphoma 2024-03-15T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heparegenix-publishes-data-for-its-first-in-class-mkk4 2024-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heparegenix-publishes-data-for-its-first-in-class-mkk4 2024-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/expired-rfa-da-25-052-tools-for-decentralized-clinical-trials 2024-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expired-rfa-da-25-052-tools-for-decentralized-clinical-trials 2024-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/protein-discovery-offers-new-hope-for-treating-aggressive-cancer 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protein-discovery-offers-new-hope-for-treating-aggressive-cancer 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-drug-trial-for-rare-chronic-kidney-disease-achieves-key 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-drug-trial-for-rare-chronic-kidney-disease-achieves-key 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mda-2024-dmd-cell-therapy-cap-1002-continues-to-preserve-limb 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mda-2024-dmd-cell-therapy-cap-1002-continues-to-preserve-limb 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gilgamesh-pharmaceuticals-awarded-14-million-national-institute-on-drug-abuse-grant-to-advance-novel-cardiac-safe-ibogaine-analog-for-the-treatment-of-opioid-use-disorder 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilgamesh-pharmaceuticals-awarded-14-million-national-institute-on-drug-abuse-grant-to-advance-novel-cardiac-safe-ibogaine-analog-for-the-treatment-of-opioid-use-disorder 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/korean-drugmakers-lead-in-biosimilar-market-and-new-denosumab-eculizumab-deals 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/korean-drugmakers-lead-in-biosimilar-market-and-new-denosumab-eculizumab-deals 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-announces-fda-approval-of-rezdiffratm-resmetirom-for-the-treatment-of-patients-with-noncirrhotic-nonalcoholic-steatohepatitis-nash-with-moderate-to-advanced-liver-fibrosis 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-announces-fda-approval-of-rezdiffratm-resmetirom-for-the-treatment-of-patients-with-noncirrhotic-nonalcoholic-steatohepatitis-nash-with-moderate-to-advanced-liver-fibrosis 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-reports-full-year-2023-financial-results-and 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-mab-reports-full-year-2023-financial-results-and 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lyt-200-receives-fda-orphan-drug-designation-for-acute-myeloid-leukemia-treatment 2024-03-13T18:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyt-200-receives-fda-orphan-drug-designation-for-acute-myeloid-leukemia-treatment 2024-03-13T18:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-zacks-analyst-blog-highlights-moderna-rapt-therapeutics-iovance-sarepta 2024-03-13T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-zacks-analyst-blog-highlights-moderna-rapt-therapeutics-iovance-sarepta 2024-03-13T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-clinical-trials-a-2024-update 2024-03-13T17:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crispr-clinical-trials-a-2024-update 2024-03-13T17:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/q4-2023-clearside-biomedical-inc-earnings-call 2024-03-13T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q4-2023-clearside-biomedical-inc-earnings-call 2024-03-13T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-inc-tyra-reports-increased-r-d-investments-amid-pipeline 2024-03-13T13:03:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-biosciences-inc-tyra-reports-increased-r-d-investments-amid-pipeline 2024-03-13T13:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/pmv-pharmaceuticals-inc-pmvp-reports-full-year-2023-financial-results 2024-03-13T13:03:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pmv-pharmaceuticals-inc-pmvp-reports-full-year-2023-financial-results 2024-03-13T13:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-se-bntx-q4-2023-earnings-call-transcript 2024-03-13T11:48:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biontech-se-bntx-q4-2023-earnings-call-transcript 2024-03-13T11:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/q4-2023-vaxart-inc-earnings-call 2024-03-13T11:03:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q4-2023-vaxart-inc-earnings-call 2024-03-13T11:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/digital-evolution-in-clinical-trials-epros-show-97-compliance-rate-in-latest-study 2024-03-13T09:01:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-evolution-in-clinical-trials-epros-show-97-compliance-rate-in-latest-study 2024-03-13T09:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/preliminary-clinical-trial-results-show-dramatic-regression-of-glioblastoma-after-next-generation-car-t-therapy 2024-03-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preliminary-clinical-trial-results-show-dramatic-regression-of-glioblastoma-after-next-generation-car-t-therapy 2024-03-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fractyl-health-announces-promising-preclinical-findings-for-glp-1-gene-therapy-in-diabetes-and-obesity 2024-03-12T11:46:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fractyl-health-announces-promising-preclinical-findings-for-glp-1-gene-therapy-in-diabetes-and-obesity 2024-03-12T11:46:03+00:00 weekly 0.7 https://trial.medpath.com/news/biovica-signs-master-service-agreement-to-support-next-generation-cdk4-6-inhibitor-development-for-breast-cancer 2024-03-12T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biovica-signs-master-service-agreement-to-support-next-generation-cdk4-6-inhibitor-development-for-breast-cancer 2024-03-12T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-receives-fda-breakthrough-therapy 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-receives-fda-breakthrough-therapy 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-combines-cisplatin-pembrolizumab-and-radiation-therapy-for-advanced-vulvar-squamous-cell-carcinoma 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-trial-combines-cisplatin-pembrolizumab-and-radiation-therapy-for-advanced-vulvar-squamous-cell-carcinoma 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nih-launches-comprehensive-clinical-trials-to-address-debilitating-long-covid-symptoms 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-launches-comprehensive-clinical-trials-to-address-debilitating-long-covid-symptoms 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/can-b-corp-acquires-cannabis-patents-valued-at-122-million-through-court-assignment 2024-03-11T12:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-b-corp-acquires-cannabis-patents-valued-at-122-million-through-court-assignment 2024-03-11T12:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/nusano-opens-radiochemistry-laboratory-to-advance-medical-radioisotope-production-for-cancer-therapy 2024-03-11T03:06:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nusano-opens-radiochemistry-laboratory-to-advance-medical-radioisotope-production-for-cancer-therapy 2024-03-11T03:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/enfortumab-vedotin-and-pembrolizumab-show-significant-survival-benefit-in-urothelial-cancer-treatment 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enfortumab-vedotin-and-pembrolizumab-show-significant-survival-benefit-in-urothelial-cancer-treatment 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-and-merck-report-promising-phase-2-results-for-once-weekly-hiv-combination-therapy 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-and-merck-report-promising-phase-2-results-for-once-weekly-hiv-combination-therapy 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-positive-top-line-results-from-its-globenewswire 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-announces-positive-top-line-results-from-its-globenewswire 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/denver-lab-developing-first-of-its-kind-tool-for-early-ovarian-cancer-detection-cbs-colorado 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/denver-lab-developing-first-of-its-kind-tool-for-early-ovarian-cancer-detection-cbs-colorado 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-long-term-32-week-data-from-the-phase-2b-trial-of-izokibep-in-hidradenitis-suppurativa-demonstrating-sustained-responses-and-deepening-clinical-benefit-improving-quality-of-life-for-patients-march-11-2024-at-08-02-am-edt-marketscreener 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-announces-long-term-32-week-data-from-the-phase-2b-trial-of-izokibep-in-hidradenitis-suppurativa-demonstrating-sustained-responses-and-deepening-clinical-benefit-improving-quality-of-life-for-patients-march-11-2024-at-08-02-am-edt-marketscreener 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-obtains-fda-approval-for-ai-discovered-cancer 2024-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recursion-obtains-fda-approval-for-ai-discovered-cancer 2024-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/benefit-of-belantamab-mafodotin-based-regimen-supported-in-multiple 2024-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benefit-of-belantamab-mafodotin-based-regimen-supported-in-multiple 2024-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-nivolumab-offers-a-promising-alternative-for-kidney-cancer-treatment 2024-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subcutaneous-nivolumab-offers-a-promising-alternative-for-kidney-cancer-treatment 2024-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promontory-therapeutics-completes-enrollment-in-phase-2-trial-of-pt-112-for-late-stage-metastatic-prostate-cancer 2024-03-08T08:02:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promontory-therapeutics-completes-enrollment-in-phase-2-trial-of-pt-112-for-late-stage-metastatic-prostate-cancer 2024-03-08T08:02:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-to-convene-advisory-committee-for-eli-lilly-s-alzheimer-s-drug-donanemab 2024-03-08T07:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-to-convene-advisory-committee-for-eli-lilly-s-alzheimer-s-drug-donanemab 2024-03-08T07:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/sexually-transmitted-infections-in-san-francisco-have 2024-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sexually-transmitted-infections-in-san-francisco-have 2024-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/als-drug-fails-large-clinical-trial-and-may-be-withdrawn-from-market-cnn 2024-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/als-drug-fails-large-clinical-trial-and-may-be-withdrawn-from-market-cnn 2024-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immuron-announces-positive-results-for-travelan-r-progressing-to-phase-3-clinical-trials-in-the-us 2024-03-07T11:06:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuron-announces-positive-results-for-travelan-r-progressing-to-phase-3-clinical-trials-in-the-us 2024-03-07T11:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder 2024-03-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder 2024-03-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-adjuvant-vs-neoadjuvant-only-pd-1-and-pd-l1-inhibitors-for 2024-03-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-adjuvant-vs-neoadjuvant-only-pd-1-and-pd-l1-inhibitors-for 2024-03-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cabozantinib-plus-nivolumab-emerges-as-preferred-first-line-treatment-for-advanced-renal-cell-carcinoma 2024-03-06T22:00:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabozantinib-plus-nivolumab-emerges-as-preferred-first-line-treatment-for-advanced-renal-cell-carcinoma 2024-03-06T22:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-for-phospho-tau-217-blood-test-for-alzheimer-s-disease 2024-03-06T19:08:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-for-phospho-tau-217-blood-test-for-alzheimer-s-disease 2024-03-06T19:08:12+00:00 weekly 0.7 https://trial.medpath.com/news/bluerock-therapeutics-reports-positive-18-month-data-in-phase-i-trial-for-parkinson-s-disease-treatment 2024-03-06T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bluerock-therapeutics-reports-positive-18-month-data-in-phase-i-trial-for-parkinson-s-disease-treatment 2024-03-06T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-initiates-phase-iii-trial-of-cadonilimab-bispecific-antibody-for-pd-l1-negative-nsclc 2024-03-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-initiates-phase-iii-trial-of-cadonilimab-bispecific-antibody-for-pd-l1-negative-nsclc 2024-03-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-cgb-500-for-atopic-dermatitis-treatment 2024-03-05T16:00:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-cgb-500-for-atopic-dermatitis-treatment 2024-03-05T16:00:28+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-teclistamab-data-shows-comparable-efficacy-to-clinical-trials-despite-higher-toxicity-rates-in-multiple-myeloma 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-teclistamab-data-shows-comparable-efficacy-to-clinical-trials-despite-higher-toxicity-rates-in-multiple-myeloma 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/camurus-announces-fda-acceptance-of-nda-submission-for-oclaiztm-for 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/camurus-announces-fda-acceptance-of-nda-submission-for-oclaiztm-for 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-ceo-details-immuno-oncology-cancer-treatment 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-ceo-details-immuno-oncology-cancer-treatment 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/transformative-trends-reshape-pharmaceutical-r-d-landscape-in-2024-ai-crispr-and-rare-disease-innovation-take-center-stage 2024-03-04T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transformative-trends-reshape-pharmaceutical-r-d-landscape-in-2024-ai-crispr-and-rare-disease-innovation-take-center-stage 2024-03-04T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trial-design-in-precision-medicine 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-clinical-trial-design-in-precision-medicine 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ucsf-trigeminal-neuralgia-clinical-trials-for-2024-san-francisco 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucsf-trigeminal-neuralgia-clinical-trials-for-2024-san-francisco 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rop-et-a-prospective-phase-iii-trial-investigating-the 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rop-et-a-prospective-phase-iii-trial-investigating-the 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-phase-3-trial-tests-efzofitimod-as-steroid-sparing-treatment-for-sarcoidosis 2024-03-01T07:16:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-phase-3-trial-tests-efzofitimod-as-steroid-sparing-treatment-for-sarcoidosis 2024-03-01T07:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/eu-clinical-trials-directive-transition-deadline-looms-companies-must-act-by-january-2025 2024-03-01T01:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-clinical-trials-directive-transition-deadline-looms-companies-must-act-by-january-2025 2024-03-01T01:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-files-marketing-authorisation-application-with-ema-for-resminostat 2024-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-files-marketing-authorisation-application-with-ema-for-resminostat 2024-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharma-receives-ind-approval-for-p53-y220c-activator-jab-30355-in-the-us 2024-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jacobio-pharma-receives-ind-approval-for-p53-y220c-activator-jab-30355-in-the-us 2024-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/niaid-halts-clemastine-arm-of-ms-trial-after-fivefold-increase-in-disease-progression 2024-02-29T18:36:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/niaid-halts-clemastine-arm-of-ms-trial-after-fivefold-increase-in-disease-progression 2024-02-29T18:36:32+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-reveals-significant-disparities-in-psoriasis-impact-across-racial-and-ethnic-groups 2024-02-29T11:26:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-research-reveals-significant-disparities-in-psoriasis-impact-across-racial-and-ethnic-groups 2024-02-29T11:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/cu-cancer-center-researchers-advance-novel-cancer-therapy-with-svc112-molecule 2024-02-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cu-cancer-center-researchers-advance-novel-cancer-therapy-with-svc112-molecule 2024-02-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fire1-completes-enrollment-in-u-s-early-feasibility-study-of 2024-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fire1-completes-enrollment-in-u-s-early-feasibility-study-of 2024-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-lifileucel-for-unresectable-or-metastatic-melanoma 2024-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-lifileucel-for-unresectable-or-metastatic-melanoma 2024-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/til-therapy-offers-new-hope-for-patients-with-metastatic-melanoma 2024-02-27T15:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/til-therapy-offers-new-hope-for-patients-with-metastatic-melanoma 2024-02-27T15:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/greenwich-lifesciences-expands-flamingo-01-phase-iii-clinical-trial-to-europe 2024-02-27T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/greenwich-lifesciences-expands-flamingo-01-phase-iii-clinical-trial-to-europe 2024-02-27T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-reduces-allergic-reactions-to-multiple-foods-in-nih-clinical-trial 2024-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibody-reduces-allergic-reactions-to-multiple-foods-in-nih-clinical-trial 2024-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/memorial-sloan-kettering-cancer-center-now-enrolling-patients-in-phase-1-2-clinical-trial-of-imunons-imnn-001-in-combination-with-bevacizumab-in-advanced-ovarian-cancer 2024-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/memorial-sloan-kettering-cancer-center-now-enrolling-patients-in-phase-1-2-clinical-trial-of-imunons-imnn-001-in-combination-with-bevacizumab-in-advanced-ovarian-cancer 2024-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pcm-trials-acquires-emvenio-research-to-expand-decentralized-clinical-trial-access-for-underrepresented-communities 2024-02-26T10:40:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pcm-trials-acquires-emvenio-research-to-expand-decentralized-clinical-trial-access-for-underrepresented-communities 2024-02-26T10:40:40+00:00 weekly 0.7 https://trial.medpath.com/news/global-rare-disease-crisis-3-5-million-uk-patients-face-critical-healthcare-challenges 2024-02-26T01:31:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-rare-disease-crisis-3-5-million-uk-patients-face-critical-healthcare-challenges 2024-02-26T01:31:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-analysis-reveals-decade-of-growth-in-rare-pediatric-disease-drug-development-through-priority-review-voucher-program 2024-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-analysis-reveals-decade-of-growth-in-rare-pediatric-disease-drug-development-through-priority-review-voucher-program 2024-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/thervacb-therapeutic-vaccine-begins-first-in-human-trial-for-chronic-hepatitis-b 2024-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thervacb-therapeutic-vaccine-begins-first-in-human-trial-for-chronic-hepatitis-b 2024-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/combination-therapy-shows-promise-for-chronic-gvhd-as-real-world-data-confirms-ruxolitinib-s-sustained-activity 2024-02-24T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-therapy-shows-promise-for-chronic-gvhd-as-real-world-data-confirms-ruxolitinib-s-sustained-activity 2024-02-24T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intrommune-therapeutics-presents-supporting-data-introducing-a 2024-02-23T23:22:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intrommune-therapeutics-presents-supporting-data-introducing-a 2024-02-23T23:22:33+00:00 weekly 0.7 https://trial.medpath.com/news/experts-highlight-key-trends-and-challenges-in-rare-disease-drug-development-for-2024 2024-02-23T07:24:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-highlight-key-trends-and-challenges-in-rare-disease-drug-development-for-2024 2024-02-23T07:24:50+00:00 weekly 0.7 https://trial.medpath.com/news/darolutamide-shows-promising-results-in-treating-metastatic-hormone-sensitive-prostate-cancer 2024-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/darolutamide-shows-promising-results-in-treating-metastatic-hormone-sensitive-prostate-cancer 2024-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designations-to-two-novel-aml-therapies 2024-02-22T16:25:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designations-to-two-novel-aml-therapies 2024-02-22T16:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionary-car-t-cell-therapy-offers-new-hope-for-autoimmune-disease-patients 2024-02-22T11:24:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revolutionary-car-t-cell-therapy-offers-new-hope-for-autoimmune-disease-patients 2024-02-22T11:24:52+00:00 weekly 0.7 https://trial.medpath.com/news/indian-pharmaceutical-giants-race-to-develop-generic-versions-of-wegovy-as-global-weight-loss-market-approaches-100-billion 2024-02-22T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indian-pharmaceutical-giants-race-to-develop-generic-versions-of-wegovy-as-global-weight-loss-market-approaches-100-billion 2024-02-22T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-pivots-beyond-covid-19-with-rsv-vaccine-launch-reports-better-than-expected-q4-profits 2024-02-22T03:54:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-pivots-beyond-covid-19-with-rsv-vaccine-launch-reports-better-than-expected-q4-profits 2024-02-22T03:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-acquires-boston-pharmaceuticals-efimosfermin-for-liver-disease-in-2-billion-deal 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-acquires-boston-pharmaceuticals-efimosfermin-for-liver-disease-in-2-billion-deal 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/india-s-indigenous-car-t-cell-therapy-revolutionizes-cancer-treatment-at-one-tenth-global-cost 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-s-indigenous-car-t-cell-therapy-revolutionizes-cancer-treatment-at-one-tenth-global-cost 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-a-mixed-response-to-a-petition-seeking-greater-clinical-trial-transparency 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-gives-a-mixed-response-to-a-petition-seeking-greater-clinical-trial-transparency 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-an-artificial-intelligence-based-clinical-trial-matching-system-for-hepatocellular-carcinoma 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluation-of-an-artificial-intelligence-based-clinical-trial-matching-system-for-hepatocellular-carcinoma 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-announces-amendment-and-extension-of-exclusive-supply-and-distribution-agreement-with-baxter-healthcare-corporation-financial-post 2024-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-announces-amendment-and-extension-of-exclusive-supply-and-distribution-agreement-with-baxter-healthcare-corporation-financial-post 2024-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-hold-on-studies-of-zelnecirnon-rpt193-in-atopic 2024-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-hold-on-studies-of-zelnecirnon-rpt193-in-atopic 2024-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immuneering-shares-rise-after-fda-fast-track-status-for 2024-02-20T14:54:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuneering-shares-rise-after-fda-fast-track-status-for 2024-02-20T14:54:06+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-glofitamab-expands-treatment-horizons-for-multiple-b-cell-lymphomas 2024-02-20T10:01:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-glofitamab-expands-treatment-horizons-for-multiple-b-cell-lymphomas 2024-02-20T10:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/atropos-health-and-seqster-partner-to-revolutionize-healthcare-data-analytics-with-ai-powered-patient-registries 2024-02-20T03:45:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atropos-health-and-seqster-partner-to-revolutionize-healthcare-data-analytics-with-ai-powered-patient-registries 2024-02-20T03:45:44+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-gets-new-tagrisso-ok-as-drug-succeeds-in 2024-02-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-gets-new-tagrisso-ok-as-drug-succeeds-in 2024-02-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cyclarity-therapeutics-advances-in-developing-a-plaque-busting-molecule-for-atherosclerosis 2024-02-19T11:53:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cyclarity-therapeutics-advances-in-developing-a-plaque-busting-molecule-for-atherosclerosis 2024-02-19T11:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-clinical-data-management-systems-revolutionize-biotech-trials 2024-02-19T05:22:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-generation-clinical-data-management-systems-revolutionize-biotech-trials 2024-02-19T05:22:12+00:00 weekly 0.7 https://trial.medpath.com/news/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/double-blind-trial-shows-comparable-efficacy-in-treatment-and-control-groups-for-gastric-symptoms 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/double-blind-trial-shows-comparable-efficacy-in-treatment-and-control-groups-for-gastric-symptoms 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/houtou-jianweiling-tablet-shows-promise-in-treating-chronic-non-atrophic-gastritis 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/houtou-jianweiling-tablet-shows-promise-in-treating-chronic-non-atrophic-gastritis 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/largest-covid-vaccine-study-yet-finds-links-to-health-conditions-bloomberg 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/largest-covid-vaccine-study-yet-finds-links-to-health-conditions-bloomberg 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-osimertinib-plus-chemo-for-egfr-mutated-nsclc 2024-02-16T21:54:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-osimertinib-plus-chemo-for-egfr-mutated-nsclc 2024-02-16T21:54:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-tigilanol-tiglate-for-soft-tissue-sarcoma-treatment 2024-02-16T18:12:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-tigilanol-tiglate-for-soft-tissue-sarcoma-treatment 2024-02-16T18:12:11+00:00 weekly 0.7 https://trial.medpath.com/news/nexicart-1-safety-and-efficacy-of-nxc-201-in-al-amyloidosis 2024-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nexicart-1-safety-and-efficacy-of-nxc-201-in-al-amyloidosis 2024-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/als-drug-from-denali-sanofi-falls-short-in-mid-stage-study 2024-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/als-drug-from-denali-sanofi-falls-short-in-mid-stage-study 2024-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adi-peg20-quadruples-three-year-survival-in-phase-3-mesothelioma-trial 2024-02-15T16:26:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adi-peg20-quadruples-three-year-survival-in-phase-3-mesothelioma-trial 2024-02-15T16:26:00+00:00 weekly 0.7 https://trial.medpath.com/news/scope-summit-2024-patient-centricity-and-ai-drive-clinical-trial-innovation 2024-02-15T07:13:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scope-summit-2024-patient-centricity-and-ai-drive-clinical-trial-innovation 2024-02-15T07:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-announces-major-milestone-by-reaching-its-interim-enrollment-target-of-90-patients-financial-post 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-announces-major-milestone-by-reaching-its-interim-enrollment-target-of-90-patients-financial-post 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-outcomes-before-and-after-prucalopride-treatment-an 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-outcomes-before-and-after-prucalopride-treatment-an 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-chemohormonal-therapy-shows-promise-for-high-risk-prostate-cancer 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-chemohormonal-therapy-shows-promise-for-high-risk-prostate-cancer 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-set-to-transform-drug-development-landscape-in-2024-from-clinical-trials-to-supply-chain-optimization 2024-02-14T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-set-to-transform-drug-development-landscape-in-2024-from-clinical-trials-to-supply-chain-optimization 2024-02-14T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/grifols-biotest-achieves-phase-3-success-for-fibrinogen-concentrate-in-acquired-deficiency-treatment 2024-02-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grifols-biotest-achieves-phase-3-success-for-fibrinogen-concentrate-in-acquired-deficiency-treatment 2024-02-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/publication-in-diabetologia-highlights-ai-s-potential-for-type-1 2024-02-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/publication-in-diabetologia-highlights-ai-s-potential-for-type-1 2024-02-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/st-jude-scientists-develop-novel-bispecific-car-t-design-to-combat-acute-myeloid-leukemia-relapse 2024-02-13T14:54:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/st-jude-scientists-develop-novel-bispecific-car-t-design-to-combat-acute-myeloid-leukemia-relapse 2024-02-13T14:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-embraces-ai-integration-in-clinical-trials-while-emphasizing-safety-and-guidance 2024-02-13T13:43:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-embraces-ai-integration-in-clinical-trials-while-emphasizing-safety-and-guidance 2024-02-13T13:43:38+00:00 weekly 0.7 https://trial.medpath.com/news/pasithea-therapeutics-announces-enrollment-opening-for-pas-004-phase-1-clinical-trial 2024-02-13T07:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pasithea-therapeutics-announces-enrollment-opening-for-pas-004-phase-1-clinical-trial 2024-02-13T07:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/hmnc-brain-health-advances-precision-psychiatry-with-novel-oral-ketamine-study-for-treatment-resistant-depression 2024-02-13T03:10:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hmnc-brain-health-advances-precision-psychiatry-with-novel-oral-ketamine-study-for-treatment-resistant-depression 2024-02-13T03:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-immunotherapy-treatment-options 2024-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-immunotherapy-treatment-options 2024-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-gsk-s-bepirovirsen-for-chronic-hepatitis-b-treatment 2024-02-12T16:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-gsk-s-bepirovirsen-for-chronic-hepatitis-b-treatment 2024-02-12T16:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-in-clinical-trials-industry-leaders-call-for-balanced-approach-at-scope-summit-2024 2024-02-12T13:05:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-in-clinical-trials-industry-leaders-call-for-balanced-approach-at-scope-summit-2024 2024-02-12T13:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stock-roundup-mrna-s-q4-results-rapt-down-on-study-results-other 2024-02-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-stock-roundup-mrna-s-q4-results-rapt-down-on-study-results-other 2024-02-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-outcomes-of-advanced-renal-cell-carcinoma-treatment-with-immune-oncology-combinations 2024-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-outcomes-of-advanced-renal-cell-carcinoma-treatment-with-immune-oncology-combinations 2024-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4dmt-presents-interim-data-from-4d-310-inglaxa-phase-1-2-clinical-trials-for-fabry-disease-cardiomyopathy-at-worldsymposiumtm-2024 2024-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4dmt-presents-interim-data-from-4d-310-inglaxa-phase-1-2-clinical-trials-for-fabry-disease-cardiomyopathy-at-worldsymposiumtm-2024 2024-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5-year-survival-outcomes-in-bladder-cancer-treatment-study 2024-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-year-survival-outcomes-in-bladder-cancer-treatment-study 2024-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-advances-tak-861-to-phase-iii-for-narcolepsy-type-1-following-positive-phase-iib-results 2024-02-09T13:51:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/takeda-advances-tak-861-to-phase-iii-for-narcolepsy-type-1-following-positive-phase-iib-results 2024-02-09T13:51:12+00:00 weekly 0.7 https://trial.medpath.com/news/oral-serds-a-new-hope-for-metastatic-breast-cancer-treatment 2024-02-07T19:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-serds-a-new-hope-for-metastatic-breast-cancer-treatment 2024-02-07T19:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/byondis-advances-novel-her2-targeting-adc-trastuzumab-duocarmazine-in-multiple-cancer-indications 2024-02-07T18:42:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/byondis-advances-novel-her2-targeting-adc-trastuzumab-duocarmazine-in-multiple-cancer-indications 2024-02-07T18:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-advances-lsd-development-program-for-major-depressive-disorder-treatment 2024-02-07T18:30:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindmed-advances-lsd-development-program-for-major-depressive-disorder-treatment 2024-02-07T18:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/cytomx-therapeutics-reports-promising-interim-phase-1-data-for-cx-2051-antibody-drug-conjugate 2024-02-07T16:43:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytomx-therapeutics-reports-promising-interim-phase-1-data-for-cx-2051-antibody-drug-conjugate 2024-02-07T16:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-efficacy-and-safety-of-iptacopan-in-pnh-with-anaemia 2024-02-07T13:56:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-efficacy-and-safety-of-iptacopan-in-pnh-with-anaemia 2024-02-07T13:56:30+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-england-launches-brca-testing-program-for-jewish-community-to-combat-cancer-risk 2024-02-07T03:43:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-england-launches-brca-testing-program-for-jewish-community-to-combat-cancer-risk 2024-02-07T03:43:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-latozinemab-breakthrough-therapy-designation-for-frontotemporal-dementia-due-to-a-progranulin-gene-mutation-ftd-grn 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-latozinemab-breakthrough-therapy-designation-for-frontotemporal-dementia-due-to-a-progranulin-gene-mutation-ftd-grn 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lb-pharmaceuticals-advances-schizophrenia-treatment-with-lb-102 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lb-pharmaceuticals-advances-schizophrenia-treatment-with-lb-102 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-upgraded-to-buy-on-successful-trial-by-investing-com 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-upgraded-to-buy-on-successful-trial-by-investing-com 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-status-to-vepdegestrant-for-er-her2-metastatic-breast-cancer 2024-02-06T18:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-vepdegestrant-for-er-her2-metastatic-breast-cancer 2024-02-06T18:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-clinical-trials-regulation-advances-harmonization-with-2025-transition-deadline 2024-02-06T04:27:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-clinical-trials-regulation-advances-harmonization-with-2025-transition-deadline 2024-02-06T04:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/metagenomi-aims-for-87m-ipo-to-advance-novel-gene-editing-platform 2024-02-06T00:05:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metagenomi-aims-for-87m-ipo-to-advance-novel-gene-editing-platform 2024-02-06T00:05:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-bnt325-db-1305-for-platinum-resistant-ovarian-cancer 2024-02-05T22:18:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-bnt325-db-1305-for-platinum-resistant-ovarian-cancer 2024-02-05T22:18:47+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-nipocalimab-shows-promise-in-treating-autoimmune-diseases 2024-02-05T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-nipocalimab-shows-promise-in-treating-autoimmune-diseases 2024-02-05T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/mpox-treatment-niaid-national-institute-of-allergy-and-infectious 2024-02-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mpox-treatment-niaid-national-institute-of-allergy-and-infectious 2024-02-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-panel-recommends-new-standards-for-pulse-oximeters-amid-bias 2024-02-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-panel-recommends-new-standards-for-pulse-oximeters-amid-bias 2024-02-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aviceda-begins-part-2-of-phase-ii-iii-trial-for-geographic-atrophy 2024-02-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aviceda-begins-part-2-of-phase-ii-iii-trial-for-geographic-atrophy 2024-02-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cabaletta-bio-announces-fda-granted-orphan-drug 2024-02-01T16:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabaletta-bio-announces-fda-granted-orphan-drug 2024-02-01T16:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/proniras-secures-4-65-in-series-b-financing 2024-02-01T15:14:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/proniras-secures-4-65-in-series-b-financing 2024-02-01T15:14:22+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-hope-for-blood-cancer-patients 2024-02-01T12:15:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatment-hope-for-blood-cancer-patients 2024-02-01T12:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/merck-signals-continued-pursuit-of-15b-deals-to-offset-future-keytruda-patent-loss 2024-02-01T03:55:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-signals-continued-pursuit-of-15b-deals-to-offset-future-keytruda-patent-loss 2024-02-01T03:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-use-of-fedratinib-for-myelofibrosis-following-ruxolitinib-failure 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-use-of-fedratinib-for-myelofibrosis-following-ruxolitinib-failure 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/usher-syndrome-market-insight-epidemiology-and-market-forecast-2034 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usher-syndrome-market-insight-epidemiology-and-market-forecast-2034 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-clinical-trial-is-launched-for-a-novel-drug-that-could-extend 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-clinical-trial-is-launched-for-a-novel-drug-that-could-extend 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-euas-for-four-monoclonal-antibody-products 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-revokes-euas-for-four-monoclonal-antibody-products 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adaptimmune-announces-u-s-fda-acceptance-of-biologics-license-application-for-afami-cel 2024-01-31T16:44:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptimmune-announces-u-s-fda-acceptance-of-biologics-license-application-for-afami-cel 2024-01-31T16:44:00+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-advances-zilebesiran-to-phase-3-cardiovascular-outcomes-trial-following-positive-kardia-3-results 2024-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-advances-zilebesiran-to-phase-3-cardiovascular-outcomes-trial-following-positive-kardia-3-results 2024-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/curiteva-receives-fda-clearance-for-world-s-first-3d-printed-trabecular-peek-lumbar-fusion-system 2024-01-30T12:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curiteva-receives-fda-clearance-for-world-s-first-3d-printed-trabecular-peek-lumbar-fusion-system 2024-01-30T12:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-neoimmunetech-s-nt-i7-for-advanced-pancreatic-cancer-treatment 2024-01-30T06:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-neoimmunetech-s-nt-i7-for-advanced-pancreatic-cancer-treatment 2024-01-30T06:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/scandion-oncology-reports-positive-phase-iia-data-in-corist-part-3-trial 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scandion-oncology-reports-positive-phase-iia-data-in-corist-part-3-trial 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-pain-drug-may-offer-alternative-to-opioids-for-acute-pain-study-finds-cnn 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experimental-pain-drug-may-offer-alternative-to-opioids-for-acute-pain-study-finds-cnn 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-high-dose-eylea-8mg-aflibercept-accepted-for-review-by-china-s-nmpa-following-uk-approval 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-s-high-dose-eylea-8mg-aflibercept-accepted-for-review-by-china-s-nmpa-following-uk-approval 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enrolled-in-rise-therapeutics-rheumatoid-arthritis 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-enrolled-in-rise-therapeutics-rheumatoid-arthritis 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-fda-acceptance-for-substantive-review-of-the-premarket-approval-application-for-alfapump-r-in-recurrent-or-refractory-ascites-due-to-liver-cirrhosis 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-announces-fda-acceptance-for-substantive-review-of-the-premarket-approval-application-for-alfapump-r-in-recurrent-or-refractory-ascites-due-to-liver-cirrhosis 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-in-reversing-age-related-metabolic-dysfunction 2024-01-28T17:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-promise-in-reversing-age-related-metabolic-dysfunction 2024-01-28T17:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-trials-restore-hearing-to-children-born-deaf 2024-01-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-trials-restore-hearing-to-children-born-deaf 2024-01-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bravyl-shows-promise-in-slowing-als-progression-study-finds 2024-01-26T12:24:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bravyl-shows-promise-in-slowing-als-progression-study-finds 2024-01-26T12:24:54+00:00 weekly 0.7 https://trial.medpath.com/news/major-pharma-giants-unite-at-biophysics-for-drug-discovery-summit-to-advance-novel-therapeutic-development 2024-01-26T06:06:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/major-pharma-giants-unite-at-biophysics-for-drug-discovery-summit-to-advance-novel-therapeutic-development 2024-01-26T06:06:32+00:00 weekly 0.7 https://trial.medpath.com/news/ema-confirms-recommendation-for-non-renewal-of 2024-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-confirms-recommendation-for-non-renewal-of 2024-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/generative-ai-set-to-transform-life-sciences-industry-in-2024-from-trust-building-to-personalized-medicine 2024-01-25T02:22:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/generative-ai-set-to-transform-life-sciences-industry-in-2024-from-trust-building-to-personalized-medicine 2024-01-25T02:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-glioblastoma-treatment-research-at-mayo-clinic 2024-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-glioblastoma-treatment-research-at-mayo-clinic 2024-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-shows-significant-survival-benefit-in-adjuvant-therapy-for-kidney-cancer 2024-01-24T13:48:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-shows-significant-survival-benefit-in-adjuvant-therapy-for-kidney-cancer 2024-01-24T13:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/experts-outline-new-approaches-to-combination-therapy-in-atopic-dermatitis-management 2024-01-23T06:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-outline-new-approaches-to-combination-therapy-in-atopic-dermatitis-management 2024-01-23T06:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-eflornithine-for-adult-pediatric-patients-with 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-eflornithine-for-adult-pediatric-patients-with 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-nivolumab-plus-ipilimumab-shows-benefit-in 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-line-nivolumab-plus-ipilimumab-shows-benefit-in 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/taiho-oncology-announces-publication-of-final-results-from-ascertain-clinical-trial 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/taiho-oncology-announces-publication-of-final-results-from-ascertain-clinical-trial 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/you-become-so-strong-duncan-b-c-family-enrolls-infant-son-in-clinical-trial-to-treat-leukemia 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/you-become-so-strong-duncan-b-c-family-enrolls-infant-son-in-clinical-trial-to-treat-leukemia 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lixte-biotechnology-s-lb-100-shows-promise-in-multiple-cancer-indications-through-novel-pp2a-inhibition 2024-01-22T09:04:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lixte-biotechnology-s-lb-100-shows-promise-in-multiple-cancer-indications-through-novel-pp2a-inhibition 2024-01-22T09:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-ramucirumab-shows-promise-in-expanding-treatment-portfolio-for-laryngeal-cancer 2024-01-22T08:58:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-ramucirumab-shows-promise-in-expanding-treatment-portfolio-for-laryngeal-cancer 2024-01-22T08:58:36+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-s-crizotinib-explores-new-frontier-in-her2-negative-breast-cancer-treatment 2024-01-22T08:56:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-s-crizotinib-explores-new-frontier-in-her2-negative-breast-cancer-treatment 2024-01-22T08:56:56+00:00 weekly 0.7 https://trial.medpath.com/news/merck-launches-phase-3-trial-testing-sacituzumab-tirumotecan-pembrolizumab-combination-in-high-risk-triple-negative-breast-cancer 2024-01-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-launches-phase-3-trial-testing-sacituzumab-tirumotecan-pembrolizumab-combination-in-high-risk-triple-negative-breast-cancer 2024-01-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/superbug-crisis-phage-therapy-offers-hope-against-antibiotic-resistance 2024-01-21T15:00:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/superbug-crisis-phage-therapy-offers-hope-against-antibiotic-resistance 2024-01-21T15:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharma-presents-data-of-glecirasib-in-patients-with-pancreatic 2024-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jacobio-pharma-presents-data-of-glecirasib-in-patients-with-pancreatic 2024-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stemcell-technologies-expands-clinical-capabilities-through-strategic-acquisitions-of-sqz-biotechnologies-and-propagenix 2024-01-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stemcell-technologies-expands-clinical-capabilities-through-strategic-acquisitions-of-sqz-biotechnologies-and-propagenix 2024-01-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/domvanalimab-combination-shows-promise-in-first-line-gastroesophageal-cancer-treatment 2024-01-18T17:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/domvanalimab-combination-shows-promise-in-first-line-gastroesophageal-cancer-treatment 2024-01-18T17:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-neurosigma-s-second-generation-monarch-etns-system-for-pediatric-adhd-treatment 2024-01-18T05:26:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-neurosigma-s-second-generation-monarch-etns-system-for-pediatric-adhd-treatment 2024-01-18T05:26:02+00:00 weekly 0.7 https://trial.medpath.com/news/early-treatment-in-weeks-after-hiv-infection-may-help-better-control-virus-long-term-study-finds-euronews 2024-01-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-treatment-in-weeks-after-hiv-infection-may-help-better-control-virus-long-term-study-finds-euronews 2024-01-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pepromene-bio-inc-announces-complete-remission-of-the-cohort-1-first-patient-treated-for-relapsed-and-refractory-b-cell-acute-lymphoblastic-leukemia-b-all-in-the-phase-1-clinical-trial-of-pmb-ct01-baffr-car-t-cells-at-city-of-hope 2024-01-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pepromene-bio-inc-announces-complete-remission-of-the-cohort-1-first-patient-treated-for-relapsed-and-refractory-b-cell-acute-lymphoblastic-leukemia-b-all-in-the-phase-1-clinical-trial-of-pmb-ct01-baffr-car-t-cells-at-city-of-hope 2024-01-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-cancer-drug-offers-kinder-alternative-to-chemotherapy-for-children 2024-01-17T01:15:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-cancer-drug-offers-kinder-alternative-to-chemotherapy-for-children 2024-01-17T01:15:24+00:00 weekly 0.7 https://trial.medpath.com/news/video-faricimab-shows-good-visual-stability-extended-healio 2024-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/video-faricimab-shows-good-visual-stability-extended-healio 2024-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-provides-positive-phase-2-clinical-updates-for-lead 2024-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-provides-positive-phase-2-clinical-updates-for-lead 2024-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-bacteriophage-therapy-summit-to-address-clinical-development-challenges-in-boston 2024-01-16T08:00:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-bacteriophage-therapy-summit-to-address-clinical-development-challenges-in-boston 2024-01-16T08:00:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-crispr-gene-editing-treatment 2024-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-crispr-gene-editing-treatment 2024-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-receives-u-s-fda-fast-track-designation-for-nx-5948 2024-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-receives-u-s-fda-fast-track-designation-for-nx-5948 2024-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-of-crinecerfont-shows-promise-in-treating-pediatric-congenital-adrenal-hyperplasia 2024-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trial-of-crinecerfont-shows-promise-in-treating-pediatric-congenital-adrenal-hyperplasia 2024-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-protein-based-blood-test-achieves-90-accuracy-in-detecting-early-stage-cancers-across-18-tumor-types 2024-01-14T18:23:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-protein-based-blood-test-achieves-90-accuracy-in-detecting-early-stage-cancers-across-18-tumor-types 2024-01-14T18:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilars-in-2024-market-evolution-promises-cost-savings-amid-industry-challenges 2024-01-14T05:55:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosimilars-in-2024-market-evolution-promises-cost-savings-amid-industry-challenges 2024-01-14T05:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-pharmaceuticals-reports-strong-financial-growth-and-advances-in-rnai-therapeutics 2024-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-pharmaceuticals-reports-strong-financial-growth-and-advances-in-rnai-therapeutics 2024-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-trends-from-jp-morgan-2024-m-a-revival-ai-integration-and-adc-renaissance-in-pharma 2024-01-12T07:15:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-trends-from-jp-morgan-2024-m-a-revival-ai-integration-and-adc-renaissance-in-pharma 2024-01-12T07:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-study-supports-second-line-axi-cel-in-r-r-lbcl-targeted-oncology 2024-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-study-supports-second-line-axi-cel-in-r-r-lbcl-targeted-oncology 2024-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rh5-1-matrix-m-vaccine-shows-promising-efficacy-against-malaria-in-african-children 2024-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rh5-1-matrix-m-vaccine-shows-promising-efficacy-against-malaria-in-african-children 2024-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nafdac-launches-electronic-clinical-trial-application-platform 2024-01-11T09:03:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nafdac-launches-electronic-clinical-trial-application-platform 2024-01-11T09:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/life-sciences-real-estate-sector-faces-four-key-challenges-in-2024-sustainability-funding-and-market-evolution 2024-01-11T01:59:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/life-sciences-real-estate-sector-faces-four-key-challenges-in-2024-sustainability-funding-and-market-evolution 2024-01-11T01:59:15+00:00 weekly 0.7 https://trial.medpath.com/news/study-evaluates-impact-of-adjuvant-chemotherapy-on-ipmn-derived-pancreatic-ductal-adenocarcinoma 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-evaluates-impact-of-adjuvant-chemotherapy-on-ipmn-derived-pancreatic-ductal-adenocarcinoma 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-european-medicines-agency-s-scientific-advisory-group 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-european-medicines-agency-s-scientific-advisory-group 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-confirms-safety-and-efficacy-of-houtou-jianweiling-tablet-for-chronic-non-atrophic-gastritis 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-confirms-safety-and-efficacy-of-houtou-jianweiling-tablet-for-chronic-non-atrophic-gastritis 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-antibodies-promising-advances-amid-adoption-challenges-in-cancer-treatment 2024-01-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bispecific-antibodies-promising-advances-amid-adoption-challenges-in-cancer-treatment 2024-01-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmather-sets-august-2025-fda-approval-goal-date-for-ketamine-product-confirms-full-funding-through-commercial-launch 2024-01-10T12:32:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmather-sets-august-2025-fda-approval-goal-date-for-ketamine-product-confirms-full-funding-through-commercial-launch 2024-01-10T12:32:36+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-advanced-technologies-reshape-clinical-trial-design-and-development-strategy 2024-01-10T04:13:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-and-advanced-technologies-reshape-clinical-trial-design-and-development-strategy 2024-01-10T04:13:59+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-advances-global-vaccine-development-with-protein-based-platform-and-matrix-m-technology 2024-01-10T02:34:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-advances-global-vaccine-development-with-protein-based-platform-and-matrix-m-technology 2024-01-10T02:34:36+00:00 weekly 0.7 https://trial.medpath.com/news/five-key-pharma-marketing-trends-reshaping-industry-strategy-in-2024 2024-01-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/five-key-pharma-marketing-trends-reshaping-industry-strategy-in-2024 2024-01-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elicio-s-eli-002-cancer-vaccine-shows-promising-results-in-phase-1-trial-for-pancreatic-and-colorectal-cancer 2024-01-10T00:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elicio-s-eli-002-cancer-vaccine-shows-promising-results-in-phase-1-trial-for-pancreatic-and-colorectal-cancer 2024-01-10T00:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-first-ustekinumab-biosimilar-uzpruvo 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-approves-first-ustekinumab-biosimilar-uzpruvo 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-iii-prostact-global-study-of 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-iii-prostact-global-study-of 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adoption-of-total-neoadjuvant-therapy-in-the-treatment 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adoption-of-total-neoadjuvant-therapy-in-the-treatment 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/largest-study-to-date-of-high-dose-methotrexate-associated 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/largest-study-to-date-of-high-dose-methotrexate-associated 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adimab-announces-2023-clinical-pipeline-update-with-12-new-partner-programs 2024-01-09T19:18:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adimab-announces-2023-clinical-pipeline-update-with-12-new-partner-programs 2024-01-09T19:18:47+00:00 weekly 0.7 https://trial.medpath.com/news/quanthealth-secures-17m-series-a-funding-to-advance-ai-powered-clinical-trial-simulations 2024-01-09T02:33:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quanthealth-secures-17m-series-a-funding-to-advance-ai-powered-clinical-trial-simulations 2024-01-09T02:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-acquires-aiolos-bio-for-1-4b-expanding-asthma-treatment-portfolio-with-novel-tslp-inhibitor 2024-01-09T01:08:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-acquires-aiolos-bio-for-1-4b-expanding-asthma-treatment-portfolio-with-novel-tslp-inhibitor 2024-01-09T01:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-highlights-adverse-events-associated-with-lenvatinib-use 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-study-highlights-adverse-events-associated-with-lenvatinib-use 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-s-mazdutide-achieves-phase-3-success-in-chinese-obesity-trial-paving-way-for-first-glp-1r-gcgr-dual-agonist-approval 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-s-mazdutide-achieves-phase-3-success-in-chinese-obesity-trial-paving-way-for-first-glp-1r-gcgr-dual-agonist-approval 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genascence-advances-first-gene-therapy-for-knee-osteoarthritis-in-phase-1b-donatello-trial 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genascence-advances-first-gene-therapy-for-knee-osteoarthritis-in-phase-1b-donatello-trial 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oks-nda-for-sh-105-in-breast-and-ovarian-cancer 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-oks-nda-for-sh-105-in-breast-and-ovarian-cancer 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-s-amvuttra-shows-significant-cardiac-benefits-in-attr-amyloidosis-patients-at-acc-25 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-s-amvuttra-shows-significant-cardiac-benefits-in-attr-amyloidosis-patients-at-acc-25 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/disitamab-vedotin-shows-promising-results-in-advanced-urothelial-carcinoma-treatment-at-2024-esmo-congress 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disitamab-vedotin-shows-promising-results-in-advanced-urothelial-carcinoma-treatment-at-2024-esmo-congress 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-receptor-agonists-show-promise-for-weight-loss-in-overweight-and-obese-individuals-without-diabetes 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-promise-for-weight-loss-in-overweight-and-obese-individuals-without-diabetes 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mobile-application-reduces-opioid-misuse-after-cesarean-section 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mobile-application-reduces-opioid-misuse-after-cesarean-section 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/doxycycline-post-exposure-prophylaxis-shows-promise-in-reducing-stis-among-msm 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doxycycline-post-exposure-prophylaxis-shows-promise-in-reducing-stis-among-msm 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stock-roundup-biib-eisai-s-drug-update-nvax-gains-on-deal-amendment 2024-01-08T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-stock-roundup-biib-eisai-s-drug-update-nvax-gains-on-deal-amendment 2024-01-08T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-fda-nod-to-azn-s-eplontersen-crl-to-mrk-s-cough-candidate 2024-01-08T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-stock-roundup-fda-nod-to-azn-s-eplontersen-crl-to-mrk-s-cough-candidate 2024-01-08T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/biolinerx-ltd-nasdaq-blrx-q3-2023-earnings-call-transcript 2024-01-08T20:03:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biolinerx-ltd-nasdaq-blrx-q3-2023-earnings-call-transcript 2024-01-08T20:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-covid-vaccines-ok-d-by-fda-escaped-convict-search-5-things-podcast 2024-01-08T15:45:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-covid-vaccines-ok-d-by-fda-escaped-convict-search-5-things-podcast 2024-01-08T15:45:22+00:00 weekly 0.7 https://trial.medpath.com/news/geovax-labs-inc-nasdaq-govx-q3-2023-earnings-call-transcript 2024-01-08T13:04:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/geovax-labs-inc-nasdaq-govx-q3-2023-earnings-call-transcript 2024-01-08T13:04:51+00:00 weekly 0.7 https://trial.medpath.com/news/revolution-medicines-inc-nasdaq-rvmd-q3-2023-earnings-call-transcript 2024-01-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revolution-medicines-inc-nasdaq-rvmd-q3-2023-earnings-call-transcript 2024-01-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/atai-life-sciences-nv-reports-q3-2023-financial-results-and-pipeline-progress 2024-01-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atai-life-sciences-nv-reports-q3-2023-financial-results-and-pipeline-progress 2024-01-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stock-roundup-aldx-evlo-down-on-setback-srrk-offers-updates-more 2024-01-08T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-stock-roundup-aldx-evlo-down-on-setback-srrk-offers-updates-more 2024-01-08T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-novo-nordisk-stocks-soar-after-weight-loss-drug-trial-boosts-outlook 2024-01-08T12:21:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-novo-nordisk-stocks-soar-after-weight-loss-drug-trial-boosts-outlook 2024-01-08T12:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/mereo-biopharma-updates-on-pipeline-progress-and-corporate-developments 2024-01-08T12:06:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mereo-biopharma-updates-on-pipeline-progress-and-corporate-developments 2024-01-08T12:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-bmy-nsclc-drug-application-gets-ema-validation 2024-01-08T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-bmy-nsclc-drug-application-gets-ema-validation 2024-01-08T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/noddy-holders-secret-throat-cancer-battle-as-wife-reveals-singer-was-told-he 2024-01-08T11:10:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/noddy-holders-secret-throat-cancer-battle-as-wife-reveals-singer-was-told-he 2024-01-08T11:10:10+00:00 weekly 0.7 https://trial.medpath.com/news/fluoguide-advances-fg001-development-for-cancer-surgery-precision 2024-01-08T11:06:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fluoguide-advances-fg001-development-for-cancer-surgery-precision 2024-01-08T11:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/inspira-iinn-advances-foothold-in-europe-with-extended-deal 2024-01-08T11:03:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspira-iinn-advances-foothold-in-europe-with-extended-deal 2024-01-08T11:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-announces-preliminary-unaudited-2023-revenue-and-2024-objectives 2024-01-08T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/karyopharm-announces-preliminary-unaudited-2023-revenue-and-2024-objectives 2024-01-08T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-gains-market-research-findings-to-guide-us-commercial-strategy 2024-01-08T08:28:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-gains-market-research-findings-to-guide-us-commercial-strategy 2024-01-08T08:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/ensysce-biosciences-highlights-2023-achievements-and-plans-for-2024 2024-01-08T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ensysce-biosciences-highlights-2023-achievements-and-plans-for-2024 2024-01-08T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-acquires-ambrx-for-2b-to-expand-antibody-drug-conjugate-portfolio-in-oncology 2024-01-08T01:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-acquires-ambrx-for-2b-to-expand-antibody-drug-conjugate-portfolio-in-oncology 2024-01-08T01:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-soligenix-orphan-drug-designation-for-dusquetide-in-behcet-s-disease-treatment 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-soligenix-orphan-drug-designation-for-dusquetide-in-behcet-s-disease-treatment 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-lutikizumab-shows-promise-in-phase-2-trial-for-hidradenitis-suppurativa-advances-to-phase-3 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-lutikizumab-shows-promise-in-phase-2-trial-for-hidradenitis-suppurativa-advances-to-phase-3 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-outlines-2024-strategic-priorities-with-focus-on-cancer-and-autoimmune-diseases 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-outlines-2024-strategic-priorities-with-focus-on-cancer-and-autoimmune-diseases 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/curevo-vaccine-announces-positive-phase-2-trial-results-for-next-generation-shingles-vaccine 2024-01-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curevo-vaccine-announces-positive-phase-2-trial-results-for-next-generation-shingles-vaccine 2024-01-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-disrupts-drug-access-with-lillydirect-new-telehealth-platform-for-obesity-and-chronic-disease-medications 2024-01-07T00:09:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-disrupts-drug-access-with-lillydirect-new-telehealth-platform-for-obesity-and-chronic-disease-medications 2024-01-07T00:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-announces-preliminary-2023-revenue-and-2024-financial-guidance 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-announces-preliminary-2023-revenue-and-2024-financial-guidance 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-unveils-vision-2030-strategic-roadmap 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-unveils-vision-2030-strategic-roadmap 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-application-submitted-for-journey-medicals-rosacea-candidate 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-application-submitted-for-journey-medicals-rosacea-candidate 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acupuncture-shows-promise-in-treating-combat-related-ptsd 2024-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acupuncture-shows-promise-in-treating-combat-related-ptsd 2024-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/allogene-therapeutics-pivots-strategy-with-pipeline-restructuring-and-22-workforce-reduction 2024-01-05T15:56:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allogene-therapeutics-pivots-strategy-with-pipeline-restructuring-and-22-workforce-reduction 2024-01-05T15:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/combat-veterans-took-a-psychedelic-drug-for-ptsd-then-this-happened 2024-01-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combat-veterans-took-a-psychedelic-drug-for-ptsd-then-this-happened 2024-01-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-announces-workforce-reduction-and-research-pause 2024-01-04T17:47:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-announces-workforce-reduction-and-research-pause 2024-01-04T17:47:00+00:00 weekly 0.7 https://trial.medpath.com/news/askbio-s-ab-1005-gene-therapy-for-parkinsons-disease-meets-primary-endpoint-in-phase-ib-trial 2024-01-04T13:47:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/askbio-s-ab-1005-gene-therapy-for-parkinsons-disease-meets-primary-endpoint-in-phase-ib-trial 2024-01-04T13:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/newamsterdam-pharma-announces-2024-strategic-priorities-and-clinical-trial-updates 2024-01-04T13:06:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newamsterdam-pharma-announces-2024-strategic-priorities-and-clinical-trial-updates 2024-01-04T13:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/quanta-therapeutics-advances-kras-directed-drug-candidates-with-fda-ind-clearance 2024-01-04T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quanta-therapeutics-advances-kras-directed-drug-candidates-with-fda-ind-clearance 2024-01-04T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-advances-obecabtagene-autoleucel-car-t-therapy-for-relapsed-refractory-all 2024-01-04T10:08:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-advances-obecabtagene-autoleucel-car-t-therapy-for-relapsed-refractory-all 2024-01-04T10:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/patient-voice-amplification-critical-for-clinical-trial-success-industry-analysis-shows-85-retention-failure-rate 2024-01-04T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-voice-amplification-critical-for-clinical-trial-success-industry-analysis-shows-85-retention-failure-rate 2024-01-04T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/accords-bla-for-its-ustekinumab-stelara-r-biosimilar-accepted-by-fda-settlement-with-janssen-permits-launch-by-15-may-2025-pearce-ip 2024-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accords-bla-for-its-ustekinumab-stelara-r-biosimilar-accepted-by-fda-settlement-with-janssen-permits-launch-by-15-may-2025-pearce-ip 2024-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-outlines-strategic-priorities-and-outlook-for-2024-and-2025 2024-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-outlines-strategic-priorities-and-outlook-for-2024-and-2025 2024-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/upstream-bio-advances-verekitug-into-phase-2-trials-for-severe-asthma-and-chronic-rhinosinusitis-with-nasal-polyps 2024-01-03T12:06:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upstream-bio-advances-verekitug-into-phase-2-trials-for-severe-asthma-and-chronic-rhinosinusitis-with-nasal-polyps 2024-01-03T12:06:18+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-drug-market-surges-major-pharma-companies-race-to-develop-novel-treatments 2024-01-03T02:13:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obesity-drug-market-surges-major-pharma-companies-race-to-develop-novel-treatments 2024-01-03T02:13:03+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-to-present-at-two-upcoming-investor 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-to-present-at-two-upcoming-investor 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/henlius-to-release-clinical-data-at-2024-asco-gi 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/henlius-to-release-clinical-data-at-2024-asco-gi 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-lung-cancer-therapy-succeeds-in-head-to-head-study-with-lcfa 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-lung-cancer-therapy-succeeds-in-head-to-head-study-with-lcfa 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spero-therapeutics-initiates-phase-3-trial-for-first-oral-carbapenem-in-us-targeting-complicated-utis 2024-01-02T13:42:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spero-therapeutics-initiates-phase-3-trial-for-first-oral-carbapenem-in-us-targeting-complicated-utis 2024-01-02T13:42:43+00:00 weekly 0.7 https://trial.medpath.com/news/pasithea-therapeutics-announces-fda-acceptance-of-ind-application-for-pas-004-in-advanced-cancer-patients 2024-01-02T13:36:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pasithea-therapeutics-announces-fda-acceptance-of-ind-application-for-pas-004-in-advanced-cancer-patients 2024-01-02T13:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-pharmaceuticals-announces-key-updates-and-2024-milestones 2024-01-02T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-pharmaceuticals-announces-key-updates-and-2024-milestones 2024-01-02T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mit-develops-wireless-implantable-device-for-continuous-insulin-production-in-type-1-diabetes 2024-01-02T02:02:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mit-develops-wireless-implantable-device-for-continuous-insulin-production-in-type-1-diabetes 2024-01-02T02:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-for-cutx-101-in-treatment-of-menkes-disease 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-for-cutx-101-in-treatment-of-menkes-disease 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/apogee-s-apg777-shows-75-day-half-life-in-phase-1-trial-for-atopic-dermatitis 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apogee-s-apg777-shows-75-day-half-life-in-phase-1-trial-for-atopic-dermatitis 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pynnacle-study-rezatapopt-pynnacle-clinical-study 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pynnacle-study-rezatapopt-pynnacle-clinical-study 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sabcs-2024-highlights-advances-in-breast-cancer-treatment 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sabcs-2024-highlights-advances-in-breast-cancer-treatment 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-requires-guillain-barre-syndrome-gbs-warning-in 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-requires-guillain-barre-syndrome-gbs-warning-in 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-chemotherapy-plus-camrelizumab-shows-promise-for-locally-advanced-cervical-cancer 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-chemotherapy-plus-camrelizumab-shows-promise-for-locally-advanced-cervical-cancer 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-intervention-treatment-in-the-first-2-weeks-following-concussion 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-intervention-treatment-in-the-first-2-weeks-following-concussion 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cryptosporidium-pi-4-k-inhibitor-edi048-is-a-gut-restricted 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cryptosporidium-pi-4-k-inhibitor-edi048-is-a-gut-restricted 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-ag-receives-paediatric-investigation-plan-waiver 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-ag-receives-paediatric-investigation-plan-waiver 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/measurable-residual-disease-assessment-prior-to 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/measurable-residual-disease-assessment-prior-to 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/annovis-bio-announces-positive-fda-notice-for 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annovis-bio-announces-positive-fda-notice-for 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pirtobrutinib-shows-high-response-rates-in-relapsed-cll-patients-with-btk-mutations 2023-12-28T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pirtobrutinib-shows-high-response-rates-in-relapsed-cll-patients-with-btk-mutations 2023-12-28T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-submits-premarket-approval-application-to-us-fda-for 2023-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-submits-premarket-approval-application-to-us-fda-for 2023-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-assisted-colonoscopy-boosts-adenoma-detection-rate-by-40-in-junior-endoscopists 2023-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-assisted-colonoscopy-boosts-adenoma-detection-rate-by-40-in-junior-endoscopists 2023-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/landmark-phase-3-mariposa-study-meets-primary 2023-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/landmark-phase-3-mariposa-study-meets-primary 2023-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bms-acquires-karuna-therapeutics-for-14-billion-betting-on-novel-schizophrenia-drug-karxt 2023-12-23T08:49:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bms-acquires-karuna-therapeutics-for-14-billion-betting-on-novel-schizophrenia-drug-karxt 2023-12-23T08:49:46+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-issues-complete-response-globenewswire 2023-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-food-and-drug-administration-issues-complete-response-globenewswire 2023-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fujirebio-launches-automated-ptau-217-plasma-assay-for-alzheimer-s-disease-research 2023-12-22T17:23:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fujirebio-launches-automated-ptau-217-plasma-assay-for-alzheimer-s-disease-research 2023-12-22T17:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/patritumab-deruxtecan-granted-priority-review-in-the-u-s-for-egfr-mutated-non-small-cell-lung-cancer-treatment 2023-12-22T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patritumab-deruxtecan-granted-priority-review-in-the-u-s-for-egfr-mutated-non-small-cell-lung-cancer-treatment 2023-12-22T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-advances-to-phase-ii-trial-for-cs-aki-treatment-in-turkey 2023-12-21T12:33:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arch-biopartners-advances-to-phase-ii-trial-for-cs-aki-treatment-in-turkey 2023-12-21T12:33:43+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilar-market-set-for-major-expansion-in-2024-ophthalmology-and-immunology-lead-growth 2023-12-21T09:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosimilar-market-set-for-major-expansion-in-2024-ophthalmology-and-immunology-lead-growth 2023-12-21T09:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-advances-microbiome-therapeutics-in-oncology 2023-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maat-pharma-advances-microbiome-therapeutics-in-oncology 2023-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mindbio-therapeutics-ceo-updates-on-phase-2-clinical-trials-progress 2023-12-20T11:56:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindbio-therapeutics-ceo-updates-on-phase-2-clinical-trials-progress 2023-12-20T11:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-radium-223-dichloride-expands-treatment-horizons-for-metastatic-prostate-cancer 2023-12-20T10:15:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-s-radium-223-dichloride-expands-treatment-horizons-for-metastatic-prostate-cancer 2023-12-20T10:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/evolution-of-treatment-landscape-shows-improved-survival-in-metastatic-colorectal-cancer 2023-12-20T10:00:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolution-of-treatment-landscape-shows-improved-survival-in-metastatic-colorectal-cancer 2023-12-20T10:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-reports-preliminary-data-from-ftd-grn-gene-therapy-trial 2023-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/passage-bio-reports-preliminary-data-from-ftd-grn-gene-therapy-trial 2023-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093-gsk 2023-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093-gsk 2023-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bridging-therapy-responses-may-outcomes-with-axi-cel 2023-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridging-therapy-responses-may-outcomes-with-axi-cel 2023-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/depression-and-cancer-how-psilocybin-from-mushrooms-can-help 2023-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/depression-and-cancer-how-psilocybin-from-mushrooms-can-help 2023-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/revive-therapeutics-advances-bucillamine-development-for-long-covid-treatment-through-manufacturing-partnership 2023-12-18T12:06:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revive-therapeutics-advances-bucillamine-development-for-long-covid-treatment-through-manufacturing-partnership 2023-12-18T12:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/ai-text-analytics-revolutionizes-clinical-trial-data-processing-and-patient-assessment 2023-12-18T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-text-analytics-revolutionizes-clinical-trial-data-processing-and-patient-assessment 2023-12-18T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-drug-sunvozertinib-shows-record-61-response-rate-against-rare-lung-cancer 2023-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-drug-sunvozertinib-shows-record-61-response-rate-against-rare-lung-cancer 2023-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-plus-lenvatinib-fails-to-meet-survival-endpoints-in-advanced-endometrial-cancer 2023-12-15T16:02:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-plus-lenvatinib-fails-to-meet-survival-endpoints-in-advanced-endometrial-cancer 2023-12-15T16:02:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-merck-s-welireg-for-advanced-kidney-cancer-expanding-treatment-options 2023-12-15T11:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-merck-s-welireg-for-advanced-kidney-cancer-expanding-treatment-options 2023-12-15T11:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/nihr-hosts-expert-panel-on-advancing-equality-and-diversity-in-clinical-research 2023-12-15T09:02:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nihr-hosts-expert-panel-on-advancing-equality-and-diversity-in-clinical-research 2023-12-15T09:02:42+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-pharmaceuticals-secures-two-key-patent-victories-for-parkinson-s-drug-nuplazid 2023-12-14T02:24:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-secures-two-key-patent-victories-for-parkinson-s-drug-nuplazid 2023-12-14T02:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/checkmate-77t-trial-shows-perioperative-nivolumab-significantly-improves-event-free-survival-in-resectable-nsclc 2023-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/checkmate-77t-trial-shows-perioperative-nivolumab-significantly-improves-event-free-survival-in-resectable-nsclc 2023-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-tigris-trial-update 2023-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-provides-tigris-trial-update 2023-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/halia-therapeutics-initiates-phase-2a-trial-of-first-in-class-nlrp3-inhibitor-ht-6184-for-lower-risk-myelodysplastic-syndromes 2023-12-13T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halia-therapeutics-initiates-phase-2a-trial-of-first-in-class-nlrp3-inhibitor-ht-6184-for-lower-risk-myelodysplastic-syndromes 2023-12-13T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-eflornithine-to-reduce-risk-of-relapse-in 2023-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-eflornithine-to-reduce-risk-of-relapse-in 2023-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/talquetamab-dose-reductions-maintain-efficacy-while-reducing-toxicities-in-relapsed-refractory-multiple-myeloma 2023-12-12T15:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/talquetamab-dose-reductions-maintain-efficacy-while-reducing-toxicities-in-relapsed-refractory-multiple-myeloma 2023-12-12T15:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/gc-biopharma-secures-44-million-who-flu-vaccine-contract-and-partners-with-canadian-firm-for-mrna-development 2023-12-12T10:33:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gc-biopharma-secures-44-million-who-flu-vaccine-contract-and-partners-with-canadian-firm-for-mrna-development 2023-12-12T10:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/plexium-advances-first-in-class-ikzf2-degrader-plx-4545-into-phase-1-clinical-trial 2023-12-12T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plexium-advances-first-in-class-ikzf2-degrader-plx-4545-into-phase-1-clinical-trial 2023-12-12T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/irlab-strengthens-patent-protection-for-pirepemat-a-novel-parkinson-s-fall-prevention-therapy 2023-12-12T06:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irlab-strengthens-patent-protection-for-pirepemat-a-novel-parkinson-s-fall-prevention-therapy 2023-12-12T06:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/hope-3-trial-of-dmd-therapy-cap-1002-to-continue-as-planned 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-3-trial-of-dmd-therapy-cap-1002-to-continue-as-planned 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-clinical-trial-of-car-t-cell-therapy-with-new 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-human-clinical-trial-of-car-t-cell-therapy-with-new 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/second-line-axi-cel-prolongs-survival-over-standard 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/second-line-axi-cel-prolongs-survival-over-standard 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iptacopan-yields-hematological-improvements-in-pnh-persistent-anemia 2023-12-11T18:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iptacopan-yields-hematological-improvements-in-pnh-persistent-anemia 2023-12-11T18:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-s-annamycin-shows-36-complete-response-rate-in-aml-phase-1b-2-trial-with-zero-cardiotoxicity 2023-12-11T13:52:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-s-annamycin-shows-36-complete-response-rate-in-aml-phase-1b-2-trial-with-zero-cardiotoxicity 2023-12-11T13:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-initiate-phase-3-study-for-adjuvant-treatment-of-non-small-cell-lung-cancer 2023-12-11T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-moderna-initiate-phase-3-study-for-adjuvant-treatment-of-non-small-cell-lung-cancer 2023-12-11T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/isatuximab-combination-therapy-achieves-superior-mrd-negativity-rates-in-newly-diagnosed-multiple-myeloma 2023-12-11T03:22:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/isatuximab-combination-therapy-achieves-superior-mrd-negativity-rates-in-newly-diagnosed-multiple-myeloma 2023-12-11T03:22:20+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-advances-two-novel-b-cell-lymphoma-therapies-in-first-in-human-trials 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-advances-two-novel-b-cell-lymphoma-therapies-in-first-in-human-trials 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-self-sampling-based-cervical-cancer-screening-strategy-during-covid-19-pandemic 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluation-of-self-sampling-based-cervical-cancer-screening-strategy-during-covid-19-pandemic 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-herbal-injections-combined-with-platinum-based-chemotherapy-improve-outcomes-in-advanced-non-small-cell-lung-cancer 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-herbal-injections-combined-with-platinum-based-chemotherapy-improve-outcomes-in-advanced-non-small-cell-lung-cancer 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/taiho-oncology-presents-real-world-study-data-on-oral-decitabine-and-cedazuridine-for-mds 2023-12-10T15:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/taiho-oncology-presents-real-world-study-data-on-oral-decitabine-and-cedazuridine-for-mds 2023-12-10T15:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/updated-odronextamab-data-from-relapsed-refractory-diffuse-globenewswire 2023-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-odronextamab-data-from-relapsed-refractory-diffuse-globenewswire 2023-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-plus-chemotherapy-shows-sustained-survival-benefit-in-early-stage-tnbc 2023-12-09T14:55:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-pembrolizumab-plus-chemotherapy-shows-sustained-survival-benefit-in-early-stage-tnbc 2023-12-09T14:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/south-korea-advances-real-world-evidence-integration-in-drug-development-and-regulatory-decision-making 2023-12-08T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/south-korea-advances-real-world-evidence-integration-in-drug-development-and-regulatory-decision-making 2023-12-08T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/news/solid-biosciences-sldb-dmd-drug-gets-fast-track-tag-stock-up 2023-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/solid-biosciences-sldb-dmd-drug-gets-fast-track-tag-stock-up 2023-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-rare-cancer-treatment-through-home-run-clinical-trials 2023-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-rare-cancer-treatment-through-home-run-clinical-trials 2023-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharma-to-present-data-of-kras-g12c-inhibitor-glecirasib-in 2023-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jacobio-pharma-to-present-data-of-kras-g12c-inhibitor-glecirasib-in 2023-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-grants-priority-review-for-elafibranor-a-potential-new-treatment-for-primary-biliary-cholangitis 2023-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-grants-priority-review-for-elafibranor-a-potential-new-treatment-for-primary-biliary-cholangitis 2023-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-receives-fda-approval-for-fabhalta-r-iptacopan-offering-superior-hemoglobin-improvement-in-the-absence-of-transfusions-as-the-first-oral-monotherapy-for-adults-with-pnh-novartis 2023-12-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-receives-fda-approval-for-fabhalta-r-iptacopan-offering-superior-hemoglobin-improvement-in-the-absence-of-transfusions-as-the-first-oral-monotherapy-for-adults-with-pnh-novartis 2023-12-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-tar-200-breakthrough-therapy-designation-for-bcg-unresponsive-nmibc 2023-12-05T17:53:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-tar-200-breakthrough-therapy-designation-for-bcg-unresponsive-nmibc 2023-12-05T17:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurocrine-biosciences-receives-breakthrough-therapy-designation-from-u-s-food-and-drug-administration-for-crinecerfont-in-congenital-adrenal-hyperplasia 2023-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurocrine-biosciences-receives-breakthrough-therapy-designation-from-u-s-food-and-drug-administration-for-crinecerfont-in-congenital-adrenal-hyperplasia 2023-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brainchild-bio-spins-out-of-seattle-children-s-to-develop 2023-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brainchild-bio-spins-out-of-seattle-children-s-to-develop 2023-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/travere-therapeutics-advances-filspari-toward-fda-approval-following-pre-nda-meeting 2023-12-04T21:42:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/travere-therapeutics-advances-filspari-toward-fda-approval-following-pre-nda-meeting 2023-12-04T21:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-therapeutics-announces-positive-results-from-phase-1a-1b-clinical-trial-of-zelnecirnon-for-atopic-dermatitis 2023-12-04T20:51:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapt-therapeutics-announces-positive-results-from-phase-1a-1b-clinical-trial-of-zelnecirnon-for-atopic-dermatitis 2023-12-04T20:51:36+00:00 weekly 0.7 https://trial.medpath.com/news/roche-acquires-carmot-therapeutics-for-2-7-billion-to-enter-obesity-drug-market 2023-12-04T11:13:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-acquires-carmot-therapeutics-for-2-7-billion-to-enter-obesity-drug-market 2023-12-04T11:13:58+00:00 weekly 0.7 https://trial.medpath.com/news/bms-advances-ipilimumab-development-for-metastatic-pancreatic-adenocarcinoma 2023-12-04T08:58:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bms-advances-ipilimumab-development-for-metastatic-pancreatic-adenocarcinoma 2023-12-04T08:58:58+00:00 weekly 0.7 https://trial.medpath.com/news/elevidys-makes-history-as-first-gene-therapy-for-dmd-but-challenges-remain 2023-12-04T07:00:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elevidys-makes-history-as-first-gene-therapy-for-dmd-but-challenges-remain 2023-12-04T07:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/novel-treatment-landscape-expands-for-uveal-melanoma-with-multiple-promising-therapies-in-development 2023-12-04T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-treatment-landscape-expands-for-uveal-melanoma-with-multiple-promising-therapies-in-development 2023-12-04T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-asia-congress-2023-oncologypro 2023-12-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-asia-congress-2023-oncologypro 2023-12-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/optimizing-outcomes-for-high-risk-non-muscle-invasive-bladder-cancer-with-pd-l-1-inhibitors 2023-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optimizing-outcomes-for-high-risk-non-muscle-invasive-bladder-cancer-with-pd-l-1-inhibitors 2023-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-rising-importance-of-real-world-data-and-evidence-in-pharmaceutical-r-d 2023-11-30T23:29:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-rising-importance-of-real-world-data-and-evidence-in-pharmaceutical-r-d 2023-11-30T23:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-secures-1-3-billion-deal-with-chong-kun-dang-for-hdac6-inhibitor-targeting-cmt-disease 2023-11-30T20:32:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-secures-1-3-billion-deal-with-chong-kun-dang-for-hdac6-inhibitor-targeting-cmt-disease 2023-11-30T20:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-pharmaceuticals-launches-phase-3-compass-pws-trial-for-carbetocin-nasal-spray-in-prader-willi-syndrome 2023-11-30T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-launches-phase-3-compass-pws-trial-for-carbetocin-nasal-spray-in-prader-willi-syndrome 2023-11-30T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-s-64cu-sar-bispsma-shows-promise-in-detecting-prostate-cancer-recurrence-in-cobra-trial 2023-11-30T00:31:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarity-s-64cu-sar-bispsma-shows-promise-in-detecting-prostate-cancer-recurrence-in-cobra-trial 2023-11-30T00:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/cretostimogene-grenadenorepvec-monotherapy-first-cg-oncology 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cretostimogene-grenadenorepvec-monotherapy-first-cg-oncology 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fresenius-kabi-and-formycon-announce-fda-submission-for-fyb202-a-ustekinumab-biosimilar-candidate 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fresenius-kabi-and-formycon-announce-fda-submission-for-fyb202-a-ustekinumab-biosimilar-candidate 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-janssen-join-wearable-maker-to-measure-scratching-and-other-health-tech-news 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/takeda-janssen-join-wearable-maker-to-measure-scratching-and-other-health-tech-news 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/an-anti-aging-drug-for-dogs-may-be-on-the-market-as-soon-as-2026-cbs-los-angeles 2023-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-anti-aging-drug-for-dogs-may-be-on-the-market-as-soon-as-2026-cbs-los-angeles 2023-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncosil-initiates-pancosil-trial-testing-percutaneous-delivery-of-radioactive-microparticles-for-pancreatic-cancer 2023-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncosil-initiates-pancosil-trial-testing-percutaneous-delivery-of-radioactive-microparticles-for-pancreatic-cancer 2023-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-cas9-technology-revolutionizes-car-t-cell-therapy-enhancing-efficacy-and-overcoming-treatment-barriers 2023-11-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crispr-cas9-technology-revolutionizes-car-t-cell-therapy-enhancing-efficacy-and-overcoming-treatment-barriers 2023-11-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/why-is-inflammation-disease-focused-acelyrin-stock-trading-lower-today-markets-insider 2023-11-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-is-inflammation-disease-focused-acelyrin-stock-trading-lower-today-markets-insider 2023-11-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-reports-blenrep-outperforms-in-phase-iii-multiple-myeloma-trial 2023-11-27T08:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-reports-blenrep-outperforms-in-phase-iii-multiple-myeloma-trial 2023-11-27T08:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/rpt193-demonstrates-greater-improvements-in-clinical 2023-11-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rpt193-demonstrates-greater-improvements-in-clinical 2023-11-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-transformative-potential-of-immunotherapy-for-glioblastoma-patients 2023-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-transformative-potential-of-immunotherapy-for-glioblastoma-patients 2023-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dxvx-advances-licensing-deal-for-ovm-200-cancer-vaccine-in-asian-markets 2023-11-24T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dxvx-advances-licensing-deal-for-ovm-200-cancer-vaccine-in-asian-markets 2023-11-24T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-secures-kras-g12d-inhibitor-in-419m-deal-with-usynova 2023-11-23T08:51:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-secures-kras-g12d-inhibitor-in-419m-deal-with-usynova 2023-11-23T08:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iib-trial-evaluates-efficacy-and-safety-of-anyu-peibo-capsules-for-major-depressive-disorder 2023-11-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iib-trial-evaluates-efficacy-and-safety-of-anyu-peibo-capsules-for-major-depressive-disorder 2023-11-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/digital-health-measures-gain-traction-in-value-based-healthcare-despite-implementation-challenges 2023-11-21T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-health-measures-gain-traction-in-value-based-healthcare-despite-implementation-challenges 2023-11-21T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-announces-fda-approval-of-ind-application-for-car-t-nxc-201-enabling-u-s-patient-dosing-biospace 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immix-biopharma-announces-fda-approval-of-ind-application-for-car-t-nxc-201-enabling-u-s-patient-dosing-biospace 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/connect-biopharma-partners-with-simcere-for-rademikibart-development-in-greater-china 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/connect-biopharma-partners-with-simcere-for-rademikibart-development-in-greater-china 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aimovig-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-first-head-to-head-migraine-prevention-study 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aimovig-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-first-head-to-head-migraine-prevention-study 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/final-data-from-phase-iia-corist-part-2-trial-shows-promising-median-overall-survival-of-10-4-months 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-data-from-phase-iia-corist-part-2-trial-shows-promising-median-overall-survival-of-10-4-months 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promis-neurosciences-initiates-phase-1a-clinical-trial-for-alzheimer-s-disease-treatment 2023-11-20T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promis-neurosciences-initiates-phase-1a-clinical-trial-for-alzheimer-s-disease-treatment 2023-11-20T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-showcases-significant-data-updates-from-kisqali-r-iptacopan-and-scemblix-r-at-sabcs-and-ash 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-showcases-significant-data-updates-from-kisqali-r-iptacopan-and-scemblix-r-at-sabcs-and-ash 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eptinezumab-demonstrates-sustained-long-term-efficacy-in-treatment-resistant-migraine-patients-over-18-months 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eptinezumab-demonstrates-sustained-long-term-efficacy-in-treatment-resistant-migraine-patients-over-18-months 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/asx-health-stocks-4dx-jumps-15pc-after-fda-clearance 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asx-health-stocks-4dx-jumps-15pc-after-fda-clearance 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/outstanding-12-month-first-in-human-data-from-xeltis-axess 2023-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/outstanding-12-month-first-in-human-data-from-xeltis-axess 2023-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-medtronic-s-minimally-invasive-device-for-hypertension-treatment 2023-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-medtronic-s-minimally-invasive-device-for-hypertension-treatment 2023-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-approves-world-s-first-crispr-gene-therapy-for-sickle-cell-disease-and-b-thalassemia 2023-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-approves-world-s-first-crispr-gene-therapy-for-sickle-cell-disease-and-b-thalassemia 2023-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biocon-biologics-secures-uk-approval-for-aflibercept-biosimilar-yesafili-expanding-european-market-access 2023-11-15T10:53:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocon-biologics-secures-uk-approval-for-aflibercept-biosimilar-yesafili-expanding-european-market-access 2023-11-15T10:53:21+00:00 weekly 0.7 https://trial.medpath.com/news/gene-editing-therapy-shows-promise-for-cholesterol-reduction-in-early-trial 2023-11-15T10:18:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-editing-therapy-shows-promise-for-cholesterol-reduction-in-early-trial 2023-11-15T10:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-secures-world-first-nhs-partnership-for-inclisiran-population-health-management 2023-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-secures-world-first-nhs-partnership-for-inclisiran-population-health-management 2023-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nimmune-biopharma-presents-positive-first-in-human-data-of-nim-1324-at-acr-convergence-2023 2023-11-14T13:16:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nimmune-biopharma-presents-positive-first-in-human-data-of-nim-1324-at-acr-convergence-2023 2023-11-14T13:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-presents-new-data-on-safety-and-efficacy-of-zolgensma-in-older-and-heavier-children-with-sma 2023-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-presents-new-data-on-safety-and-efficacy-of-zolgensma-in-older-and-heavier-children-with-sma 2023-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elafibranor-shows-significant-efficacy-in-phase-iii-trial-for-primary-biliary-cholangitis 2023-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elafibranor-shows-significant-efficacy-in-phase-iii-trial-for-primary-biliary-cholangitis 2023-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-moves-prospects-drop-after-phase-iii-ovarian-cancer-trial 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipeline-moves-prospects-drop-after-phase-iii-ovarian-cancer-trial 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/padcev-and-keytruda-double-bladder-cancer-survival 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/padcev-and-keytruda-double-bladder-cancer-survival 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-and-mmv-develop-novel-malaria-treatment-for-infants-under-5kg-addressing-critical-treatment-gap 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-and-mmv-develop-novel-malaria-treatment-for-infants-under-5kg-addressing-critical-treatment-gap 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ftc-challenges-over-100-drug-delivery-device-patents-in-orange-book-enforcement-action 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ftc-challenges-over-100-drug-delivery-device-patents-in-orange-book-enforcement-action 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-ianalumab-achieves-primary-endpoint-in-phase-iii-itp-trial-offering-potential-for-extended-treatment-free-periods 2023-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-ianalumab-achieves-primary-endpoint-in-phase-iii-itp-trial-offering-potential-for-extended-treatment-free-periods 2023-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-ianalumab-becomes-first-targeted-therapy-to-show-efficacy-in-sjogren-s-disease-phase-iii-trials 2023-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-ianalumab-becomes-first-targeted-therapy-to-show-efficacy-in-sjogren-s-disease-phase-iii-trials 2023-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-rna-drug-zilebesiran-delivers-six-month-blood-pressure-control-with-single-injection 2023-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experimental-rna-drug-zilebesiran-delivers-six-month-blood-pressure-control-with-single-injection 2023-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/in-lung-cancer-j-j-data-amount-to-latest-salvo-against-astrazeneca 2023-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-lung-cancer-j-j-data-amount-to-latest-salvo-against-astrazeneca 2023-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-leqvio-as-first-line-monotherapy-for-cholesterol-management 2023-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-leqvio-as-first-line-monotherapy-for-cholesterol-management 2023-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-takeda-s-adzynma-as-first-treatment-for-ultra-rare-blood-clotting-disorder-cttp 2023-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-takeda-s-adzynma-as-first-treatment-for-ultra-rare-blood-clotting-disorder-cttp 2023-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-version-of-diabetes-drug-mounjaro-for 2023-11-08T17:59:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-version-of-diabetes-drug-mounjaro-for 2023-11-08T17:59:27+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-base-editing-therapy-achieves-first-clinical-cure-of-beta-thalassaemia 2023-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-base-editing-therapy-achieves-first-clinical-cure-of-beta-thalassaemia 2023-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-slrn-reports-q3-2023-financial-results-key-clinical-trials-progressing 2023-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-slrn-reports-q3-2023-financial-results-key-clinical-trials-progressing 2023-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/participant-engagement-and-adherence-to-providing 2023-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/participant-engagement-and-adherence-to-providing 2023-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-to-know-about-biosimilar-for-stelara-that-can-treat-psorasis 2023-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-to-know-about-biosimilar-for-stelara-that-can-treat-psorasis 2023-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/learnings-from-real-world-evidence-of-faricimab-in-namd-and-dme-part-1 2023-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/learnings-from-real-world-evidence-of-faricimab-in-namd-and-dme-part-1 2023-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-cosentyx-fails-to-meet-primary-endpoint-in-phase-iii-giant-cell-arteritis-trial 2023-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-cosentyx-fails-to-meet-primary-endpoint-in-phase-iii-giant-cell-arteritis-trial 2023-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-medicine-pioneers-ai-driven-drug-discovery-with-multimodal-transformers-and-robotic-labs 2023-11-03T06:28:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insilico-medicine-pioneers-ai-driven-drug-discovery-with-multimodal-transformers-and-robotic-labs 2023-11-03T06:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/lexeo-therapeutics-launches-100m-ipo-to-advance-gene-therapy-pipeline 2023-11-03T02:04:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexeo-therapeutics-launches-100m-ipo-to-advance-gene-therapy-pipeline 2023-11-03T02:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-s-lisaftoclax-receives-fda-clearance-for-global-phase-iii-trial-in-cll-sll 2023-11-03T01:17:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascentage-pharma-s-lisaftoclax-receives-fda-clearance-for-global-phase-iii-trial-in-cll-sll 2023-11-03T01:17:45+00:00 weekly 0.7 https://trial.medpath.com/news/blood-cancer-treatment-breakthrough 2023-11-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blood-cancer-treatment-breakthrough 2023-11-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eledon-s-tegoprubart-shows-promise-in-phase-1b-kidney-transplant-trial-with-superior-organ-function-preservation 2023-11-02T13:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eledon-s-tegoprubart-shows-promise-in-phase-1b-kidney-transplant-trial-with-superior-organ-function-preservation 2023-11-02T13:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-arexvy-dominates-rsv-vaccine-market-with-1-2b-projected-sales-outpacing-pfizer-s-abrysvo 2023-11-02T01:33:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-s-arexvy-dominates-rsv-vaccine-market-with-1-2b-projected-sales-outpacing-pfizer-s-abrysvo 2023-11-02T01:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-pharmaceuticals-stock-is-plummeting-after-biotech-benzinga 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acurx-pharmaceuticals-stock-is-plummeting-after-biotech-benzinga 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kisqali-shows-enhanced-efficacy-in-younger-breast-cancer-patients-with-33-risk-reduction 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kisqali-shows-enhanced-efficacy-in-younger-breast-cancer-patients-with-33-risk-reduction 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-advances-pediatric-asciminib-trial-for-chronic-myeloid-leukemia-with-novel-dosing-strategy 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-advances-pediatric-asciminib-trial-for-chronic-myeloid-leukemia-with-novel-dosing-strategy 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alfasigma-acquires-galapagos-jak-inhibitor-jyseleca-in-eur170-million-deal 2023-11-01T00:48:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alfasigma-acquires-galapagos-jak-inhibitor-jyseleca-in-eur170-million-deal 2023-11-01T00:48:28+00:00 weekly 0.7 https://trial.medpath.com/news/endpoints-for-clinical-trials-in-ophthalmology 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endpoints-for-clinical-trials-in-ophthalmology 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/doxycycline-postexposure-prophylaxis-for-prevention 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doxycycline-postexposure-prophylaxis-for-prevention 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-voquezna-r-vonoprazan-tablets-for-erosive-gerd-treatment 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-voquezna-r-vonoprazan-tablets-for-erosive-gerd-treatment 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novartis-cosentyx-r-as-the-first-new-biologic-treatment-option-for-hidradenitis-suppurativa-patients-in-nearly-a-decade 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-novartis-cosentyx-r-as-the-first-new-biologic-treatment-option-for-hidradenitis-suppurativa-patients-in-nearly-a-decade 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-teprotumumab-in-patients-with-thyroid-eye-disease 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-teprotumumab-in-patients-with-thyroid-eye-disease 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-srpt-to-seek-approval-for-dmd-therapy-even-after-drug-trial-failed-bloomberg 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-srpt-to-seek-approval-for-dmd-therapy-even-after-drug-trial-failed-bloomberg 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-protac-vepdegestrant-shows-promise-for-esr1-mutant-breast-cancer-in-phase-2-trial 2023-10-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-protac-vepdegestrant-shows-promise-for-esr1-mutant-breast-cancer-in-phase-2-trial 2023-10-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/edgewise-therapeutics-expands-edg-5506-clinical-program-with-new-duchenne-trial-for-gene-therapy-recipients 2023-10-27T16:47:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/edgewise-therapeutics-expands-edg-5506-clinical-program-with-new-duchenne-trial-for-gene-therapy-recipients 2023-10-27T16:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-s-resminostat-receives-orphan-drug-designation-from-the-european 2023-10-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-s-resminostat-receives-orphan-drug-designation-from-the-european 2023-10-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mirikizumab-omvoh-for-ulcerative-colitis 2023-10-26T22:58:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-mirikizumab-omvoh-for-ulcerative-colitis 2023-10-26T22:58:10+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-plans-to-submit-bla-for-subcutaneous-lecanemab-following-promising-results 2023-10-26T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-plans-to-submit-bla-for-subcutaneous-lecanemab-following-promising-results 2023-10-26T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-supports-amivantamab-plus-lazertinib-over 2023-10-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trial-supports-amivantamab-plus-lazertinib-over 2023-10-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-santhera-s-drug-for-rare-muscular-dystrophy 2023-10-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-santhera-s-drug-for-rare-muscular-dystrophy 2023-10-26T00:00:00+00:00 weekly 0.7